Regulatory elements and related methods
Engineered promoters with specific nucleotide sequences and regulatory elements enhance the expression of therapeutic proteins and RNA transcripts, addressing inefficiencies in conventional methods and improving therapeutic efficacy.
Patent Information
- Application Number
- PCT/US2026/026669
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-05
- Filing Date
- 2026-05-05
- Publication Date
- 2026-11-12
AI Technical Summary
Existing technologies face challenges in efficiently expressing therapeutic proteins and RNA transcripts using conventional promoters, which often result in suboptimal expression levels and limited therapeutic efficacy.
Development of engineered promoters with nucleotide sequences identical or with variations to SEQ ID NOS: 1-9, combined with regulatory elements like ITRs, enhancers, and UTRs, to enhance the expression of therapeutic proteins and RNA transcripts.
The engineered promoters significantly increase the expression of therapeutic proteins and RNA transcripts, providing improved therapeutic outcomes by optimizing transcriptional regulation and delivery.
Smart Images

Figure IMGF000043_0001 
Figure IMGF000044_0001 
Figure IMGF000050_0001
Abstract
Description
Attorney Docket No.: 62801.89W001REGULATORY ELEMENTS AND RELATED METHODS RELATED APPLICATIONS
[0001] This application claims priority to U.S. Serial No.: 63 / 799,889, filed May 5, 2025, the entire contents of which is incorporated herein by reference.1. FIELD
[0002] This disclosure relates to transcriptional regulatory elements, including promoters and nucleic acid molecules {e.g., DNA molecules) comprising one or more of the same. The disclosure further relates to pharmaceutical compositions comprising the same for the use in the expression of proteins in a subject, e.g., for treating diseases.2. BACKGROUND
[0003] Promoters are nucleic acid sequences that can be operably connected to a nucleic acid sequence encoding a RNA transcript {e.g., tRNA) or protein e.g., operably connected upstream of the coding sequence) that mediate initiation of transcription of the coding sequence through the binding of relevant proteins {e.g., RNA polymerase, transcription factors, etc.) to the promoter sequence. The resulting transcription produces an RNA molecule. The RNA molecule can encode a protein or the RNA molecule can itself serve a biological function {e.g., a tRNA, rRNA). Promoters can influence e.g., the rate of transcription of coding sequences to which they are operably connected.3. SUMMARY
[0004] Provided herein are, inter alia, promoters for use e.g., in the expression of one or more protein or RNA transcript of interest. Further provided herein are nucleic acid molecules {e.g., DNA molecules) comprising one or more promoter described herein (or a combination thereof) and an open reading frame encoding a protein or RNA transcript of interest {e.g., a therapeutic protein) (and pharmaceutical compositions comprising the same). Further provided herein are methods of utilizing any of the foregoing in e.g., methods of expressing a protein or RNA transcript of interest, and methods of treating a disease.
[0005] As such, in one aspect, provided herein are isolated DNA molecules comprising an engineered promoter comprising a nucleotide sequence at least 85%, 86%, 87%, 88%, 89%, 90%,Attorney Docket No.: 62801.89W00191%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the nucleotide sequence set forth in any one of SEQ ID NOS: 1-8.
[0006] In one aspect, provided herein are isolated DNA molecule comprising, in the following order, an engineered promoter comprising a nucleotide sequence at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%. 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the nucleotide sequence set forth in any one of SEQ ID NOS: 1-8; and an open reading frame encoding an RNA transcript or protein.
[0007] For the sake of clarity, it should be understood that each of the following embodiments is applicable to each of the foregoing aspects as if directly recited after each aspect.
[0008] In some embodiments, the engineered promoter comprises a nucleotide sequence at least 90%, 91%, 92%, 93%, 94%. 95%, 96%, 97%, 98%, 99%, or 100% identical to the nucleotide sequence set forth in any one of SEQ ID NOS: 1-8. In some embodiments, the engineered promoter comprises a nucleotide sequence at least 95%, 96%, 97%, 98%, 99%, or 100% identical to the nucleotide sequence set forth in any one of SEQ ID NOS: 1-8. In some embodiments, the engineered promoter comprises the nucleotide sequence set forth in any one of SEQ ID NOS: 1-8.
[0009] In some embodiments, the nucleotide sequence of the engineered promoter is less than 100% (e.g., less than 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, or 90%) identical to the nucleotide sequence set forth in SEQ ID NO: 9. In some embodiments, the nucleotide sequence of the engineered promoter comprises at least one e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39) nucleotide variation (e.g., substitution) relative to the nucleotide sequence set forth in SEQ ID NO: 9.
[0010] In one aspect, provided herein are isolated DNA molecules comprising an engineered promoter comprising a nucleotide sequence at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%. 90%, 91%, 92%, 93%. 94%, 95%, 96%, 97%. 98%, 99%, identical to the nucleotide sequence set forth in SEQ ID NO: 9 and comprises one or more nucleotide variation (e.g., substitution) relative to the nucleotide sequence set forth in SEQ ID NO: 9.
[0011] For the sake of clarity, it should be understood that each of the following embodiments is applicable to each of the foregoing aspects as if directly recited after each aspect.
[0012] In some embodiments, the engineered promoter can increase expression of a transcript or protein encoded by the open reading frame, relative to a DNA molecule comprising a referenceAttorney Docket No.: 62801.89W001promoter. In some embodiments, the engineered promoter can increase expression of a transcript or protein encoded by the open reading frame, relative to a DNA molecule comprising a reference promoter comprising the nucleotide sequence set forth in SEQ ID NO: 9.
[0013] In some embodiments, the DNA molecule comprises an inverted terminal repeat (ITR). In some embodiments, the DNA molecule comprises a 5' ITR and a 3' ITR. In some embodiments, the DNA molecule comprises, in the following order, a 5' ITR, the engineered promoter, the open reading frame, and a 3' ITR.
[0014] In some embodiments, the DNA molecule comprises one or more regulatory elements (e.g., transcriptional regulatory elements). In some embodiments, the DNA molecule comprises one or more transcriptional regulatory elements. In some embodiments, the DNA molecule comprises an enhancer. In some embodiments, the DNA molecule comprises an intron. In some embodiments, the DNA molecule comprises transcription termination sequence. In some embodiments, the DNA molecule comprises a posttranscriptional regulatory element. In some embodiments, the DNA molecule comprises a poly(A) signal sequence. In some embodiments, the DNA molecule comprises one or more untranslated region (UTR). In some embodiments, the DNA molecule comprises a 5' untranslated region. In some embodiments, the DNA molecule comprises a 3' UTR. In some embodiments, the DNA molecule comprises a 5' UTR and a 3' UTR.
[0015] In some embodiments, the open reading frame encodes a protein. In some embodiments, the protein is a therapeutic protein. In some embodiments, the protein (e.g., therapeutic protein) is an immunogen (e.g., viral, bacterial, fungal). In some embodiments, the protein (e.g., therapeutic protein) comprises an antibody (or a functional fragment or variant thereof) or a fusion protein. In some embodiments, the protein (e.g., therapeutic protein) is a hormone, enzyme, growth factor, blood protein, a clotting factor, transcription factor, cytokine, chemokine, chimeric antigen receptor, T-cell receptor, or nuclease (e.g., endonuclease).
[0016] In some embodiments, the open reading frame encodes an RNA transcript. In some embodiments, the RNA transcript is a tRNA, miRNA, siRNA, antisense oligonucleotides (ASO), IncRNA, rRNA, microRNA, piRNA, snoRNA, snRNA, exRNA, scaRNA, Y RNA, or hnRNA.
[0017] In some embodiments, the DNA molecule comprises a plurality of open reading frames, each encoding an RNA transcript or protein. In some embodiments, each open reading frame of the plurality encodes a protein. In some embodiments, each open reading frame of the plurality encodes a different protein. In some embodiments, each open reading frame of theAttorney Docket No.: 62801.89W001plurality encodes an RNA transcript. In some embodiments, each open reading frame of the plurality encodes a different RNA transcript.
[0018] In one aspect, provided herein are vectors comprising a DNA molecule described herein. In some embodiments, the vector is a plasmid or a viral vector.
[0019] In one aspect, provided herein are carriers comprising a DNA molecule described herein or a vector described herein. In some embodiments, the earner is a lipid nanoparticle (LNP), liposome, lipoplex, or nanoliposome. In some embodiments, the carrier is an LNP. In some embodiments, the LNP comprises a cationic lipid, a neutral lipid, a cholesterol, and / or a PEG lipid. In some embodiments, the LNP comprises a cationic lipid, a neutral lipid, a cholesterol, and a PEG lipid. In some embodiments, the LNP has a mean particle size of between 80 nm and 160 nm.
[0020] In one aspect, provided herein is a cell (e.g., host cell) or a population of cells (e.g., a population of host cells) comprising a DNA molecule described herein, a vector described herein, or a carrier described herein.
[0021] In one aspect, provided herein are pharmaceutical compositions comprising a DNA molecule described herein, a vector described herein, a carrier described herein, or a cell or population of cells described herein, and a pharmaceutically acceptable excipient.
[0022] In one aspect, provided herein are vaccine compositions comprising a DNA molecule described herein, a vector described herein, a carrier described herein, a cell or population of cells described herein, or a pharmaceutical composition described herein. In some embodiments, the protein (e.g., therapeutic protein) comprises an immunogen.
[0023] In one aspect, provided herein are kits comprising a DNA molecule described herein, a vector described herein, a carrier described herein, a cell or population of cells described herein, a pharmaceutical composition described herein, or a vaccine composition described herein, and optionally comprising instructions for use of the foregoing.
[0024] In one aspect, provided herein are in vitro methods of making a protein (e.g., a therapeutic protein), the method comprising (a) culturing a population of cells in vitro; (b) introducing a DNA molecule described herein, a vector described herein, or a carrier described herein, to the population of cells; and (c) culturing the population of cells under conditions and for a period of time sufficient to allow for expression of the protein (e.g., therapeutic protein); and (d) optionally isolating and / or purifying the expressed protein (e.g., therapeutic protein).
[0025] In one aspect, provided herein are methods of delivering a DNA molecule, a vector, orAttorney Docket No.: 62801.89W001a carrier to a cell, the method comprising delivering to the cell a DNA molecule described herein, a vector described herein, a carrier described herein, a cell or population of cells described herein, a pharmaceutical composition described herein, or a vaccine composition described herein, to thereby deliver the DNA molecule, the vector, or the carrier to the cell. In some embodiments, the method is in vitro. In some embodiments, the cell is in vitro or ex vivo. In some embodiments, the cell is in a subject.
[0026] In one aspect, provided herein are methods of delivering a DNA molecule, a vector, a carrier, a cell, vaccine composition, or pharmaceutical composition to a subject in need thereof, the method comprising administering to the subject a DNA molecule described herein, a vector described herein, a carrier described herein, a cell or population of cells described herein, a pharmaceutical composition described herein, or a vaccine composition described herein, to thereby deliver the DNA molecule, the vector, the carrier, the cell, the vaccine composition, or the pharmaceutical composition to the subject.
[0027] In one aspect, provided herein are methods of expressing a protein (e.g., a therapeutic protein) in a cell, the method comprising delivering to the cell a DNA molecule described herein, a vector described herein, a carrier described herein, a cell or population of cells described herein, a pharmaceutical composition described herein, or a vaccine composition described herein, to thereby express the protein in the cell. In some embodiments, the method is in vitro. In some embodiments, the cell is in vitro or ex vivo. In some embodiments, the cell is in a subject.
[0028] In one aspect, provided herein are methods of expressing a protein (e.g., a therapeutic protein) in a subject in need thereof, the method comprising administering to the subject a DNA molecule described herein, a vector described herein, a carrier described herein, a cell or population of cells described herein, a pharmaceutical composition described herein, or a vaccine composition described herein, to thereby express the protein (e.g., therapeutic protein) in the subject.
[0029] In one aspect, provided herein are methods of treating, ameliorating, or preventing a disease in a subject in need thereof, the method comprising administering to the subject a DNA molecule described herein, a vector described herein, a carrier described herein, a cell or population of cells described herein, a pharmaceutical composition described herein, or a vaccine composition described herein, to thereby treat, ameliorate, or prevent the disease in the subject.
[0030] In some embodiments, the disease is a proinflammatory disease (e.g., an autoimmuneAttorney Docket No.: 62801.89W001disease), an immunosuppressive disease, a cancer, a hormone related disease, a growth factor related disease, a blood clotting disease, or a genetic disease,
[0031] In one aspect, provided herein are methods of treating, ameliorating, or preventing a disease in a subject in need thereof, the method comprising administering to the subject the protein made by a method described herein (or a pharmaceutical composition comprising the same), to thereby treat, ameliorate, or prevent the disease in the subject.
[0032] In some embodiments, the disease is a proinflammatory disease (e.g., an autoimmune disease), an immunosuppressive disease, a cancer, a hormone related disease, a growth factor related disease, a blood clotting disease, or a genetic disease.4. DETAILED DESCRIPTION
[0033] The inventors have, inter alia, designed novel promoters to, e.g., effectively express one or more protein or RNA transcript of interest (e.g., in vitro or in vivo). Accordingly, the promoters described herein (and nucleic acid molecules e.g., DNA molecules) comprising one or more of the same) are useful for the production of proteins (e.g., therapeutic proteins) and RNA transcripts; and for the delivery to or expression of proteins (e.g., therapeutic proteins) or transcripts in a human, e.g., for the treatment of diseases. As such, the current disclosure provides, inter alia, promoters and nucleic acid molecules (e.g., DNA molecules) comprising one or more of the same, and pharmaceutical compositions comprising the same for the use in the expression of proteins and RNA transcripts (e.g., in vitro or in vivo).TABLE OF CONTENTS4.1 Definitions4.2 Promoters4.3 Exemplary Properties of Promoters and Nucleic Acid Molecules Comprising the Same4.4 DNA Molecules4.4.1 Codon Optimization4.5 Regulatory Elements4.5.1 Enhancers4.5.2 Introns4.5.3 Inverted Terminal Repeats (ITRs)Attorney Docket No.: 62801.89W0014.5.4 Untranslated Regions (UTRs)4.5.5 Transcription Termination Sequence4.5.6 Posttranscriptional Regulatory Elements (PREs)4.5.7 Poly(A) Signal Sequence4.6 Open Reading Frames4.6.1 Proteins (e.g., Therapeutic Proteins)4.6.2 RNA Transcripts4.7 Methods of Making Nucleic Acid Molecules4.8 Vectors4.9 Carriers4.9.1 Lipid Based Carriers / Lipid Nanoformulations4.9.1.1 Cationic Lipids (Positively Charged) and Ionizable Lipids4.9.1.2 Non-Cationic Lipids (e.g., Phospholipids)4.9.1.3 Structural Lipids4.9.1.4 Polymers and Polyethylene Glycol (PEG) - Lipids4.9.1.5 Percentages of Lipid Nanoformulation Components4.10 Cells4.11 Vaccine Compositions4.12 Pharmaceutical Compositions4.13 Kits4.14 Methods of Use4.14.1 Delivery4.14.2 Protein Expression & Manufacturing4.14.3 Treatment, Amelioration, and Prevention of Diseases4.1 Definitions
[0034] The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.
[0035] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which the claimed subject matter belongs. It is to be understood that the foregoing general description and the following detailedAttorney Docket No.: 62801.89W001description are exemplary and explanatory only and are not restrictive of any subject matter claimed.
[0036] In this application, the use of the singular includes the plural unless specifically stated otherwise. For example, as used in the specification and the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise. Furthermore, use of the term “including” as well as other forms, such as “include.” “includes,” and “included,” is not limiting.
[0037] It is understood that wherever aspects are described herein with the language “comprising,” otherwise analogous aspects described in terms of “consisting of’ and “consisting essentially of’ are also provided.
[0038] The term “and / or” where used herein is to be taken as specific disclosure of each of the two specified features or components with or without the other. Thus, the term “and / or” as used in a phrase such as “A and / or B” herein is intended to include “A and B,” “A or B,” “A” (alone), and “B” (alone). Likewise, the term “and / or” as used in a phrase such as “A, B, and / or C” is intended to encompass each of the following aspects: A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone).
[0039] As described herein, any concentration range, percentage range, ratio range or integer range is to be understood to include the value of any integer within the recited range and, when appropriate, fractions thereof (such as one tenth and one hundredth of an integer), unless otherwise indicated.
[0040] The term “about” refers to a value or composition that is within an acceptable error range for the particular value or composition as determined by one of ordinary skill in the art, which will depend in part on how the value or composition is measured or determined, i.e., the limitations of the measurement system. When particular values or compositions are provided in the application and claims, unless otherwise stated, the meaning of “about” should be assumed to be within an acceptable error range for that particular value or composition.
[0041] Where proteins and / or polypeptides are described herein, it is understood that nucleic acid molecules e.g., RNA {e.g., mRNA) or DNA nucleic acid molecules) encoding the protein are also provided herein.
[0042] Where proteins, polypeptides, nucleic acid molecules, vectors, carriers, etc. are described herein, it is understood that isolated forms of the proteins, polypeptides, nucleic acidAttorney Docket No.: 62801.89W001molecules, vectors, carriers, etc. are also provided herein.
[0043] Where proteins, polypeptides, nucleic acid molecules, etc. are described herein, it is understood that recombinant forms of the proteins, polypeptides, nucleic acid molecules, etc. are also provided herein.
[0044] Where proteins or sets of proteins are described herein, it is understood that both proteins comprising the primary structure are provided herein as well as proteins folded into their three-dimensional structure (i.e., tertiary or quaternary structure) are provided herein.
[0045] Where proteins are described herein, it is understood that functional variants, functional fragment, and functional variants and fragments are provided herein. It is understood that the terms “functional fragment or variant,” “functional fragment or functional variant,” “functional fragment and / or functional variant” and the like - provide specific disclosure of proteins that are functional fragments, functional variants, and functional fragments and functional variants (of the reference protein).
[0046] As used herein, the term “administering” refers to the physical introduction of an agent, e.g., a therapeutic agent (or a precursor of the therapeutic agent that is metabolized or altered within the body of the subject to produce the therapeutic agent in vivo) (e.g., a therapeutic protein) or a composition (e.g., a pharmaceutical composition comprising the therapeutic agent (e.g., therapeutic protein)) to a subject, using any of the various methods and delivery systems known to those skilled in the art. Administering can also be performed, for example, once, a plurality of times, and / or over one or more extended periods. Therapeutic agents include agents whose effect is intended to be preventative (i.e., prophylactic). The term administering includes selfadministration by the subject and administration by another.
[0047] As used herein, the term “antibody” or “antibodies” is used in the broadest sense and encompasses various immunoglobulin (Ig) (e.g., human Ig (hlg)) structures, including, but not limited to monoclonal antibodies, polyclonal antibodies, multispecific (e.g., bispecific, trispecific) antibodies, and antibody fragments so long as they exhibit the desired antigen-binding activity (i.e., antigen binding fragments as defined herein). The term antibody thus includes, for example, full-length antibodies; antigen-binding fragments of full-length antibodies; molecules comprising antibody CDRs, VH regions, and / or VL regions; and antibody-like scaffolds (e.g., fibronectins). Examples of antibodies include, without limitation, monoclonal antibodies, polyclonal antibodies, monospecific antibodies, multispecific antibodies, human antibodies, humanized antibodies,Attorney Docket No.: 62801.89W001chimeric antibodies, camelized antibodies, intrabodies, affybodies, diabodies, tribodies, heteroconjugate antibodies, antibody-drug conjugates, single domain antibodies (e.g.,VHH, (VHH)2), single chain antibodies, single-chain Fvs (scFv; (scFv ), Fab fragments (e.g., Fab, single chain Fab (scFab), F(ab’)2 fragments, di sulf ide-linked Fvs (sdFv), Fc fusions (e.g., Fab-Fc, scFv-Fc, VHH-Fc, (SCFV)2-FC, (VHH)2-FC). and antigen-binding fragments of any of the above, and conjugates or fusion proteins comprising any of the above. Antibodies can be of Ig isotype (e.g., IgG, IgE, IgM, IgD, or IgA), any class (e.g., IgGi, IgG2, IgGs, IgG4, IgAi or IgA2), or any subclass (e.g., IgG2a or IgG2b) of Ig). In certain embodiments, antibodies described herein are IgG antibodies, or a class (e.g., human IgGi or IgG4) or subclass thereof. In some embodiments, the antibody is a human, humanized, or chimeric IgGi or IgG4 monoclonal antibody. In some embodiments, the term antibodies refers to a monoclonal or polyclonal antibody population.
[0048] As used herein, the terms “circRNA,” “circular RNA molecule,” are used interchangeably and refer to an RNA molecule that has a structure having no free ends (i.e., no free 3' and / or 5' ends), for example an RNA molecule that forms a circular or end-less structure through covalent (e.g., covalently closed) or non-covalent bonds. The circular RNA molecule may be e.g., a covalently closed RNA molecule.
[0049] As used herein, the term “co-administering” and the like refers to the physical introduction of different therapeutic agents (or a precursor of the therapeutic agent that is metabolized or altered within the body of the subject to produce the therapeutic agent in vivo) (e.g., a therapeutic protein)) or different compositions (e.g., different pharmaceutical compositions each comprising a different therapeutic agent (e.g., a different therapeutic protein)) to the same subject. The different therapeutic agents or compositions (e.g., pharmaceutical compositions) may be administered simultaneously, at essentially the same time, or sequentially.
[0050] As used herein, the term “disease” refers to any abnormal condition that impairs physiological function. The term is used broadly to encompass any disorder, illness, abnormality, pathology, sickness, condition, or syndrome in which physiological function is impaired, irrespective of the nature of the etiology. The term disease includes infection (e.g., viral, bacterial, fungal, yeast, parasitic infection).
[0051] As used herein, the term “derived from,” with reference to a nucleic acid molecule refers to a nucleic acid molecule that has at least 70% sequence identity to a reference nucleic acid molecule (e.g., a naturally occurring nucleic acid molecule) or a fragment thereof. The termAttorney Docket No.: 62801.89W001“derived from,” with reference to a protein refers to a protein that comprises an amino acid sequence that has at least 70% sequence identity to the amino acid sequence of a reference protein (e.g., a naturally occurring protein). The term “derived from” as used herein does not denote any specific process or method for obtaining the nucleic acid molecule, polypeptide, or protein. For example, the nucleic acid molecule, polypeptide, or protein can be recombinantly produced or chemically synthesized.
[0052] The terms “DNA” molecule and “polydeoxyribonucleotide” are used interchangeably herein and refer to macromolecules that include multiple deoxyribonucleotides that are polymerized via phosphodiester bonds. Deoxyribonucleotides are nucleotides in which the sugar is deoxyribose.
[0053] As used herein, the term “enhancer” refers to a nucleic acid sequence that which typically acts on the activity of a promoter in the cis location and thus stimulates the transcription of a coding region operably connected to the promoter. Usually, the effect of an enhancer is fairly independent of the position and orientation and therefore it may be positioned directly or indirectly 5’ or 3’ of a promoter. The enhancer may be located in the immediate vicinity of the coding region or the promoter, or at a considerable distance from the promoter.
[0054] The term “functional variant” as used herein in reference to a protein refers to a protein that comprises at least one but no more than 15%, not more than 12%, no more than 10%, no more than 8% amino acid variation (e.g., substitution, deletion, addition) compared to the amino acid sequence of a reference protein, wherein the protein retains at least one particular function of the reference protein. Not all functions of the reference protein (e.g., wild type) need be retained by the functional variant of the protein. In some instances, one or more functions are selectively reduced or eliminated. In some embodiments, the reference protein is a wild type protein.
[0055] The term “functional fragment” as used herein in reference to a protein refers to a fragment of a reference protein that retains at least one particular function. Not all functions of the reference protein need be retained by a functional fragment of the protein. In some instances, one or more functions are selectively reduced or eliminated. In some embodiments, the reference protein is a wild type protein.
[0056] As used herein, the term “fusion protein” and grammatical equivalents thereof refers to a protein that comprises at least one polypeptide operably connected to another polypeptide, wherein the first and second polypeptides are not naturally found operably connected together. ForAttorney Docket No.: 62801.89W001example, the first and second polypeptides of the fusion protein are each derived from different proteins. The at least two polypeptides of the fusion protein can be directly operably connected through a peptide bond; or can be indirectly operably connected through a linker (e.g., a peptide linker). Therefore, for example, the term fusion polypeptide encompasses embodiments, wherein Polypeptide A is directly operably connected to Polypeptide B through a peptide bond (Polypeptide A - Polypeptide B), and embodiments, wherein Polypeptide A is operably connected to Polypeptide B through a peptide linker (Polypeptide A - peptide linker - Polypeptide B).
[0057] As used herein, the term “heterologous”, when used to describe a first element in reference to a second element means that the first element and second element do not exist in nature disposed as described. For example, a polypeptide comprising a “heterologous moiety” means a polypeptide that is joined to a moiety (e.g., small molecule, polypeptide, nucleic acid molecule, carbohydrate, lipid, synthetic polymer (e.g., polymers of PEG), etc.) that is not joined to the polypeptide in nature.
[0058] As used herein, the term “immunogen” refers to a substance (e.g., a peptide or protein) that is capable of inducing an immune response (e.g., an adaptive immune response) in a subject (e.g., a human).
[0059] As used herein, the term “intron” refers to a non-coding nucleotide portion of a sequence that is transcribed and subsequently removed by splicing during formation of the mature RNA.
[0060] The term “inverted terminal repeat” or “ITR” as used herein refers to the art-recognized regions found at the 5' and 3' termini of adeno associated virus (AAV) genomes which function in cis as origins of DNA replication and as packaging signals for the viral genome.
[0061] As used herein, the term “isolated” with reference to a protein or polynucleotide refers to a protein or polynucleotide that is substantially free of other cellular components with which it is associated in the natural state.
[0062] The terms “nucleic acid molecule” and “polynucleotide” are used interchangeably herein and refer to a polymer of DNA or RNA. The nucleic acid molecule can be single-stranded or double-stranded; contain natural, non-natural, or altered nucleotides; and contain a natural, nonnatural, or altered intemucleotide linkage, such as a phosphoroamidate linkage or a phosphorothioate linkage, instead of the phosphodiester found between the nucleotides of an unmodified nucleic acid molecule. Nucleic acid molecules include, but are not limited to, allAttorney Docket No.: 62801.89W001nucleic acid molecules which are obtained by any means available in the art, including, without limitation, recombinant means, e.g., the cloning of nucleic acid molecules from a recombinant library or a cell genome, using ordinary cloning technology and polymerase chain reaction, and the like, and by synthetic means. The skilled artisan will appreciate that, except where otherwise noted, nucleic acid sequences set forth in the instant application will recite thymidine (T) in a representative DNA sequence but where the sequence represents RNA (e.g., mRNA), the thymidines (Ts) would be substituted for uracils (Us). Thus, any of the RNA polynucleotides encoded by a DNA identified by a particular sequence identification number may also comprise the corresponding RNA (e.g., mRNA) sequence encoded by the DNA, where each thymidine (T) of the DNA sequence is substituted with uracil (U).
[0063] As used herein, the term “open reading frame” or “ORF” refers to a region of a nucleic acid molecule (e.g., RNA molecule) that encodes a protein or functional RNA transcript (e.g., a tRNA). When an ORF encodes a protein, the ORF will typically include a plurality of nucleotide triads, each of which can code for an amino acid and is termed as a codon.
[0064] As used herein, the term “operably connected” refers to the linkage of two moieties in a functional relationship such that each moiety can mediate its function post linkage. For example, a polypeptide is operably connected to another polypeptide when they are linked (either directly or indirectly via a peptide linker) in frame such that both polypeptides are functional (e.g., a fusion protein described herein). Or for example, a transcription regulatory polynucleotide e.g., a promoter, enhancer, or other expression control element is operably linked to a polynucleotide that encodes a protein if it affects the transcription of the polynucleotide that encodes the protein. Operable connection of the moieties can be direct or indirect (e.g., operably linked through another moiety).
[0065] As used herein, a “poly(A) signal sequence” or “polyadenylation signal sequence” encompasses a recognition region necessary for endonuclease cleavage of an RNA transcript that is followed by the poly adenylation consensus sequence A ATA A A. A polyadenylation signal sequence provides a “polyA site”, i.e., a site on a RNA transcript to which adenine residues will be added by post-transcriptional polyadenylation.
[0066] As used herein, a “posttranscriptional regulatory element” refers to a non-coding portion of a nucleotide sequence that is transcribed and functions to regulate post-transcription RNA molecules. PREs can function by, e.g., promoting RNA export from the nucleus to theAttorney Docket No.: 62801.89W001cytoplasm, enhancing 3' end processing and stability. See, e.g., Sun J, Li D, Hao Y, Zhang Y, Fan W, Fu J, Hu Y, Liu Y, Shao Y. Posttranscriptional regulatory elements enhance antigen expression and DNA vaccine efficacy. DNA Cell Biol. 2009 May;28(5):233-40. doi: 10.1089 / dna.2009.0862. PMID: 19388846; PMCID: PMC2719066, the entire contents of which are incorporated by reference herein for all purposes.
[0067] As used herein, the term “pharmaceutical composition” means a composition that is suitable for administration to an animal, e.g., a human subject, and comprises a therapeutic agent and a pharmaceutically acceptable carrier or diluent. A “pharmaceutically acceptable carrier or diluent” means a substance for use in contact with the tissues of human beings and / or non-human animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable therapeutic benefit / risk ratio.
[0068] As used herein, the term “promoter” refers to a nucleic acid sequence (e.g., DNA sequence) that can be operably connected to a nucleic acid sequence encoding a transcript (e.g., tRNA) or protein (e.g., operably connected upstream of the coding sequence) that mediates initiation of transcription of the coding sequence through the recruitment of relevant proteins (e.g., RNA polymerase, transcription factors, etc.) to the promoter (e.g., through binding of one or more of the proteins to a portion of the promoter sequence). The resulting transcription produces an RNA molecule. The RNA molecule can encode a protein (e.g., an mRNA molecule) or the RNA molecule can itself serve a biological function (e.g., a tRNA, rRNA). Promoters can influence e.g., the rate of transcription of coding sequences to which they are operably connected.
[0069] As used herein, the terms “protein” and “polypeptide” refers to a polymer of at least 2 (e.g., at least 5) amino acids linked by a peptide bond. The term “polypeptide” does not denote a specific length of the polymer chain of amino acids. It is common in the art to refer to shorter polymers of amino acids (e.g., approximately 2-50 amino acids) as peptides; and to refer to longer polymers of amino acids (e.g., approximately over 50 amino acids) as polypeptides. However, the terms “peptide” and “polypeptide” and “protein” are used interchangeably herein. In some embodiments, the protein is folded into its three-dimensional structure. Where polypeptides are contemplated herein, it should be understood that proteins folded into their three-dimensional structure are also provided herein.
[0070] As used herein, the term “regulatory element” is a moiety, such as a nucleic acid sequence, that modifies transcription of an open reading frame within a transcribable DNAAttorney Docket No.: 62801.89W001molecule.
[0071] The terms “RNA” molecule and “polyribonucleotide” are used interchangeably herein and refer to macromolecules that include multiple ribonucleotides that are polymerized via phosphodiester bonds. Ribonucleotides are nucleotides in which the sugar is ribose. RNA may contain modified nucleotides; and contain natural, non-natural, or altered intemucleotide linkages, such as a phosphoroamidate linkage or a phosphorothioate linkage, instead of the phosphodiester found between the nucleotides of an unmodified nucleic acid molecule.
[0072] As used herein, the term “subject” includes any animal, such as a human or other animal. In embodiments, the subject is a vertebrate animal (e.g., mammal, bird, fish, reptile, or amphibian). In embodiments, the subject is a human. In embodiments, the subject is a non-human mammal. In embodiments, the subject is a non-human mammal such as a non-human primate (e.g., monkeys, apes), ungulate (e.g., cattle, buffalo, sheep, goat, pig, camel, llama, alpaca, deer, horses, donkeys), carnivore (e.g., dog, cat), rodent (e.g., rat, mouse), or lagomorph (e.g., rabbit). In embodiments, the subject is a bird, such as a member of the avian taxa Galliformes (e.g., chickens, turkeys, pheasants, quail), Anseriformes (e.g., ducks, geese), Paleaognathae (e.g., ostriches, emus), Columbiformes (e.g., pigeons, doves), or Psittaciformes (e.g., parrots).
[0073] As used herein, the term “therapeutic protein” or “therapeutic polypeptide” refers to a protein that is intended for the prevention, treatment, and / or amelioration of a disease. The therapeutic protein may have a direct therapeutic effect or an indirect therapeutic effect. For example, the therapeutic protein may target a cell to a specific target (e.g., a target cell or tissue), wherein the cell (e.g., an agent, e.g., a protein secreted from the cell) mediates a direct therapeutic effect. The term also includes proteins intended for prophylactic (preventive) use (e.g., use in vaccines, etc.).
[0074] As used herein, the term “therapeutically effective amount” of a therapeutic agent (e.g., a therapeutic protein) refers to any amount of the therapeutic agent that, when used alone or in combination with another therapeutic agent, protects a subject against the onset of a disease (or infection) or promotes disease (or infection) regression evidenced by a decrease in severity of disease of infection symptoms, an increase in frequency and duration of disease or infection symptom-free periods, or a prevention of impairment or disability due to the disease or infection affliction. The ability of a therapeutic agent to promote disease regression can be evaluated using a variety of methods known to the skilled practitioner, such as in human subjects during clinicalAttorney Docket No.: 62801.89W001trials, in animal model systems predictive of efficacy in humans, or by assaying the activity of the agent in in vitro assays.
[0075] As used herein, the term “transcription termination sequence” refers to a sequence that is operably connected (directly or indirectly) to the 3' end of an open reading frame and functions to terminate transcription. In specific embodiments, the transcription termination sequence is a poly(A) signal (e.g., described herein).
[0076] As used herein, the terms “treat,” treating,” “treatment,” and the like refer to reducing, ameliorating, or preventing a disease or infection and / or symptom(s) associated therewith or obtaining a desired pharmacologic and / or physiologic effect. It will be appreciated that, although not precluded, treating a disease or infection does not require that the disease or infection, or symptom(s) associated therewith be completely eliminated or prevented. In some embodiments, the effect is therapeutic, i.e., without limitation, the effect partially or completely reduces, diminishes, abrogates, abates, alleviates, decreases the intensity of, or cures a disease and / or adverse symptom attributable to the disease or infection. In some embodiments, the effect is preventative, i.e., the effect protects or prevents an occurrence or reoccurrence of a disease or infection. To this end, the presently disclosed methods comprise administering a therapeutically effective amount of a composition as described herein.
[0077] As used herein, an “untranslated region” or “UTR” refers to a non-coding portion of nucleic acid sequence that is not translated.
[0078] As used herein, the term “variant” or “variation” with reference to a polynucleotide, refers to a polynucleotide sequence that comprises at least one substitution, alteration, inversion, addition, or deletion of nucleotide compared to a reference polynucleotide sequence. As used herein, the term “variant” or “variation” with reference to a protein refers to a peptide or protein that comprises at least one substitution, alteration, inversion, addition, or deletion of an amino acid residue compared to a reference protein.4.2 Promoters
[0001] Provided herein are, promoters, e.g., for use in the expression of target proteins and / or RNA transcripts (e.g., in vitro or in vivo). As described above, promoters are nucleic acid sequences (e.g., DNA sequences) that can be operably connected to a nucleic acid sequence encoding an RNA transcript (e.g., tRNA) or protein (e.g., operably connected upstream of theAttorney Docket No.: 62801.89W001coding sequence) that mediates initiation of transcription of the coding sequence through the recruitment of relevant proteins (e.g., RNA polymerase, transcription factors, etc.) to the promoter (e.g., through binding of one or more of the proteins to a portion of the promoter sequence). The resulting transcription produces an RNA molecule. The RNA molecule can encode a protein e.g., an mRNA molecule) or the RNA molecule can itself serve a biological function (e.g., a tRNA, rRNA). Promoters can influence e.g., the rate of transcription of coding sequences to which they are operably connected.
[0002] The nucleotide sequence of an exemplary reference promoter is set forth in Table 1.Table 1. The Nucleotide Sequence of Exemplary Reference Promoter.SEQDescription Nucleotide SequenceID NO TGTAATCCATAACCACTCTCAGGAAATGACGTATGATAGCCAATCAGAATTGReference AGTATTAAACCTATATAAGCTGCTGCACTTCCTGATTCAATCAGACTGCATC CGGTCTCCGGCGAGTGAACATCTCTGGAAAAAGCTCCACGCTTGTGGTGAGT 9 PromoterCT AC
[0003] Provided herein are promoters (and DNA molecules comprising the same). The nucleotide sequence of promoters-1-8 (SEQ ID NOS: 1-8, respectively) is set forth below in Table 2.Table 2. The Nucleotide Sequence of Promoters.SEQPromoterNucleotide Sequence ID ID NO GGTGATCCATAACCACTCCCAGGAAATGACGTATGACAGCCAATCAGCATCGAG1 CATTAAACCTATATAAGCCGCTGCACTTCCTGATTTCGTCAGACTGCATCCGAT 1 CTCCGGCGAGTGAACATCTCTGGAAAGAGCTCCACGCATGTGGTGAGTCTAC TGTGATCCATAAACACGCCCAGGAAGTGACGTATGACAACCAATCAGCATTGAG2 CATTTATCCTATATAAACCGATGCACTTCCGGATTCCATCAGACTGCATCCGAT 2 CTCCGGCGAGTGAACATCTCTGGGAAAAGCTCCACGCTTGTGGTGAGTCTAC GGTAATCCATAACCACGCCCAGGAAGTGACGTATGTTAGCCAATCAGAATCGAG3 CATTAAACCTATATAAGCTGATGCACTTCCGCATTCAATCAGACTGCATCCGAT 3 CTCCGGCGAGTGAACATCTCTGGAAAGAGCTCCACGCATGTGGTGAGTCTAC TGTAATCCATAACCACGCCCAGGAAGTGACGTATGTTAGCCAATCAGCATTGAG4 CATTTAACCTATATAAGCCGCTGCACTTCCTCATTTAGTCAGACTGCATCCGAT 4 CTCCGGCGAGTGAACATCTCTGGAAAAAGCTCCACGCATGTGGTGAGTCTAC TGTAATCCATAAACACGCCCAGGAAATGACGTATGTTAGCCAATCAGAATCGAG5 TATTTATCCTATATAAACTGCTGCACTTCCGGATCTAGTCAGACTGCATCCGAT 5 CTCCGGCGAGTGAACATCTCTGGGAAGAGCTCCACGCTTGTGGTGAGTCTAC TGTAATCCATAACCACTCCCAGGAAATGACGTATGTTAGCCAATCAGCATTGAG6 CATTAATCCTATATAAGCTGCTGCACTTCCTCATCTAATCAGACTGCATCCGAT 6CTCCGGCGAGTGAACATCTCTGGGAAAAGCTCCACGCATGTGGTGAGTCTACAttorney Docket No.: 62801.89W001GGTGATCCATAAACACGCCCAGGAAGTGACGTATGTCAGCCAATCAGCATTGAG7 TATAAAACCTATATAAGCCGCTGCACTTCCGGATCTCGTCAGACTGCATCCGAT 7 CTCCGGCGAGTGAACATCICTGGAAAAAGCTCCACGCGTGTGGTGAGTCTAC TGTGATCCATAACCACTCCCAGGAAATGACGTATGACAACCAATCAGAATTGAG8 CATAAAACCTATATAAACTGATGCACTTCCGGATTTAGTCAGACTGCATCCGAT 8CTCCGGCGAGTGAACATCTCTGAGAAGAGATCCACGCTCGTGGTGAGTCTAC
[0004] In some embodiments, the promoter is isolated. In some embodiments, promoter is engineered. In some embodiments, promoter is isolated and engineered.
[0005] In some embodiments, the nucleotide sequence of promoter comprises a nucleotide sequence at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the nucleotide sequence of a promoter set forth in Table 2. In some embodiments, the nucleotide sequence of promoter comprises a nucleotide sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the nucleotide sequence of a promoter set forth in Table 2. In some embodiments, the nucleotide sequence of promoter comprises a nucleotide sequence at least 95%, 96%, 97%, 98%, 99%, or 100% identical to the nucleotide sequence of a promoter set forth in Table 2. In some embodiments, the nucleotide sequence of promoter comprises the nucleotide sequence of a promoter set forth in Table 2.
[0006] In some embodiments, the nucleotide sequence of promoter comprises a nucleotide sequence at least 85%. 86%, 87%, 88%, 89%, 90%. 91%. 92%, 93%, 94%, 95%, 96%. 97%. 98%, 99%, or 100% identical to the nucleotide sequence of any one of promoters-1-8. In some embodiments, the nucleotide sequence of promoter comprises a nucleotide sequence at least 90%, 91%, 92%, 93%. 94%, 95%, 96%, 97%. 98%. 99%, or 100% identical to the nucleotide sequence of any one of promoters-1-8. In some embodiments, the nucleotide sequence of promoter comprises a nucleotide sequence at least 95%, 96%. 97%, 98%, 99%, or 100% identical to the nucleotide sequence of any one of promoters-1-8. In some embodiments, the nucleotide sequence of promoter comprises the nucleotide sequence of any one of promoters-1-8.
[0007] In some embodiments, the nucleotide sequence of promoter comprises a nucleotide sequence at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the nucleotide sequence set forth in any one of SEQ ID NOS: 1-8. In some embodiments, the nucleotide sequence of promoter comprises a nucleotide sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the nucleotide sequence set forth in any one of SEQ ID NOS: 1-8. In some embodiments, the nucleotide sequence of promoter comprises a nucleotide sequence at least 95%, 96%, 97%, 98%, 99%, or 100%Attorney Docket No.: 62801.89W001identical to the nucleotide sequence set forth in any one of SEQ ID NOS: 1-8. In some embodiments, the nucleotide sequence of promoter comprises the nucleotide sequence set forth in any one of SEQ ID NOS: 1-8.
[0008] In some embodiments, the nucleotide sequence of the promoter consists of a nucleotide sequence at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the nucleotide sequence of a promoter set forth in Table 2. In some embodiments, the nucleotide sequence of the promoter consists of a nucleotide sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%. 98%, 99%, or 100% identical to the nucleotide sequence of a promoter set forth in Table 2. In some embodiments, the nucleotide sequence of the promoter consists of a nucleotide sequence at least 95%, 96%, 97%, 98%, 99%, or 100% identical to the nucleotide sequence of a promoter set forth in Table 2. In some embodiments, the nucleotide sequence of the promoter consists of the nucleotide sequence of a promoter set forth in Table 2.
[0009] In some embodiments, the nucleotide sequence of the promoter consists of a nucleotide sequence at least 85%. 86%, 87%, 88%, 89%, 90%. 91%. 92%, 93%, 94%, 95%, 96%. 97%. 98%, 99%, or 100% identical to the nucleotide sequence of any one of promoters-1-8. In some embodiments, the nucleotide sequence of the promoter consists of a nucleotide sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the nucleotide sequence of any one of promoters-1-8. In some embodiments, the nucleotide sequence of the promoter consists of a nucleotide sequence at least 95%, 96%, 97%, 98%. 99%, or 100% identical to the nucleotide sequence of any one of promoters-1-8. In some embodiments, the nucleotide sequence of the promoter consists of the nucleotide sequence of any one of promoters-1-8.
[0010] In some embodiments, the nucleotide sequence of the promoter consists of a nucleotide sequence at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the nucleotide sequence set forth in any one of SEQ ID NOS: 1-8. In some embodiments, the nucleotide sequence of the promoter consists of a nucleotide sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the nucleotide sequence set forth in any one of SEQ ID NOS: 1-8. In some embodiments, the nucleotide sequence of the promoter consists of a nucleotide sequence at least 95%, 96%, 97%, 98%, 99%, or 100% identical to the nucleotide sequence set forth in any one of SEQ ID NOS: 1-8. In some embodiments, the nucleotide sequence of the promoter consists of the nucleotide sequence set forth in any one of SEQ ID NOS: 1-8.Attorney Docket No.: 62801.89W001
[0011] In some embodiments, the nucleotide sequence of the promoter is less than 100% (e.g., less than 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, or 90%) identical to the nucleotide sequence set forth in SEQ ID NO: 9. In some embodiments, the nucleotide sequence of the promoter comprises at least one (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34. 35, 36, 37, 38, 39) nucleotide variation (e.g., substitution) relative to the nucleotide sequence set forth in SEQ ID NO: 9. In some embodiments, the nucleotide sequence of the promoter comprises a nucleotide sequence at least 80%, 81%, 82%, 83%. 84%, 85%, 86%, 87%, 88%, 89%. 90%, 91%, 92%, 93%, 94%, 95%. 96%, 97%, 98%, 99%, identical to the nucleotide sequence set forth in SEQ ID NO: 9 and comprises one or more nucleotide variation (e.g., substitution) relative to the nucleotide sequence set forth in SEQ ID NO: 9.
[0012] In one aspect, provided herein are DNA molecules comprising a promoter described herein. In some embodiments, the DNA molecule is isolated. In some embodiments, the promoter is engineered.
[0013] In some embodiments, the nucleotide sequence of the promoter of the DNA molecule comprises a nucleotide sequence at least 85%, 86%, 87%. 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the nucleotide sequence of a promoter set forth in Table 2. In some embodiments, the nucleotide sequence of the promoter of the DNA molecule comprises a nucleotide sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the nucleotide sequence of a promoter set forth in Table 2. In some embodiments, the nucleotide sequence of the promoter of the DNA molecule comprises a nucleotide sequence at least 95%. 96%, 97%, 98%, 99%, or 100% identical to the nucleotide sequence of a promoter set forth in Table 2. In some embodiments, the nucleotide sequence of the promoter of the DNA molecule comprises the nucleotide sequence of a promoter set forth in Table 2.
[0014] In some embodiments, the nucleotide sequence of the promoter of the DNA molecule comprises a nucleotide sequence at least 85%, 86%, 87%. 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the nucleotide sequence of any one of promoters-1-8. In some embodiments, the nucleotide sequence of the promoter of the DNA molecule comprises a nucleotide sequence at least 90%, 91%. 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the nucleotide sequence of any one of promoters- 1-8. In some embodiments,Attorney Docket No.: 62801.89W001the nucleotide sequence of the promoter of the DNA molecule comprises a nucleotide sequence at least 95%, 96%, 97%, 98%, 99%, or 100% identical to the nucleotide sequence of any one of promoters- 1-8. In some embodiments, the nucleotide sequence of the promoter of the DNA molecule comprises the nucleotide sequence of any one of promoters- 1-8.
[0015] In some embodiments, the nucleotide sequence of the promoter of the DNA molecule comprises a nucleotide sequence at least 85%. 86%. 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the nucleotide sequence set forth in any one of SEQ ID NOS: 1-8. In some embodiments, the nucleotide sequence of the promoter of the DNA molecule comprises a nucleotide sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the nucleotide sequence set forth in any one of SEQ ID NOS: 1-8. In some embodiments, the nucleotide sequence of the promoter of the DNA molecule comprises a nucleotide sequence at least 95%, 96%, 97%, 98%, 99%, or 100% identical to the nucleotide sequence set forth in any one of SEQ ID NOS: 1-8. In some embodiments, the nucleotide sequence of the promoter of the DNA molecule comprises the nucleotide sequence set forth in any one of SEQ ID NOS: 1-8.
[0016] In some embodiments, the nucleotide sequence of the promoter of the DNA molecule consists of a nucleotide sequence at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the nucleotide sequence of a promoter set forth in Table 2. In some embodiments, the nucleotide sequence of the promoter of the DNA molecule consists of a nucleotide sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the nucleotide sequence of a promoter set forth in Table 2. In some embodiments, the nucleotide sequence of the promoter of the DNA molecule consists of a nucleotide sequence at least 95%, 96%, 97%, 98%, 99%, or 100% identical to the nucleotide sequence of a promoter set forth in Table 2. In some embodiments, the nucleotide sequence of the promoter of the DNA molecule consists of the nucleotide sequence of a promoter set forth in Table 2.
[0017] In some embodiments, the nucleotide sequence of the promoter of the DNA molecule consists of a nucleotide sequence at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the nucleotide sequence of any one of promoters-1-8. In some embodiments, the nucleotide sequence of the promoter of the DNA molecule consists of a nucleotide sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, orAttorney Docket No.: 62801.89W001100% identical to the nucleotide sequence of any one of promoters- 1 -8. In some embodiments, the nucleotide sequence of the promoter of the DNA molecule consists of a nucleotide sequence at least 95%, 96%. 97%, 98%, 99%. or 100% identical to the nucleotide sequence of any one of promoters- 1-8. In some embodiments, the nucleotide sequence of the promoter of the DNA molecule consists of the nucleotide sequence of any one of promoters- 1-8.
[0018] In some embodiments, the nucleotide sequence of the promoter of the DNA molecule consists of a nucleotide sequence at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%. 98%, 99%, or 100% identical to the nucleotide sequence set forth in any one of SEQ ID NOS: 1-8. In some embodiments, the nucleotide sequence of the promoter of the DNA molecule consists of a nucleotide sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the nucleotide sequence set forth in any one of SEQ ID NOS: 1- 8. In some embodiments, the nucleotide sequence of the promoter of the DNA molecule consists of a nucleotide sequence at least 95%, 96%, 97%, 98%, 99%, or 100% identical to the nucleotide sequence set forth in any one of SEQ ID NOS: 1-8. In some embodiments, the nucleotide sequence of the promoter of the DNA molecule consists of the nucleotide sequence set forth in any one of SEQ ID NOS: 1-8.
[0019] In some embodiments, the nucleotide sequence of the promoter of the DNA molecule is less than 100% (e.g., less than 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, or 90%) identical to the nucleotide sequence set forth in SEQ ID NO: 9. In some embodiments, the nucleotide sequence of the promoter of the DNA molecule comprises at least one (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39) nucleotide variation (e.g., substitution) relative to the nucleotide sequence set forth in SEQ ID NO: 9. In some embodiments, the nucleotide sequence of the promoter of the DNA molecule comprises a nucleotide sequence at least 80%, 81%, 82%, 83%, 84%, 85%. 86%, 87%. 88%, 89%, 90%. 91%, 92%, 93%. 94%, 95%. 96%, 97%, 98%. 99%, identical to the nucleotide sequence set forth in SEQ ID NO: 9 and comprises one or more nucleotide variation (e.g., substitution) relative to the nucleotide sequence set forth in SEQ ID NO: 9.
[0020] In some embodiments, the promoter is from about 100-200, 110-200, 120-200, 130-200, 140-200, 150-200, 160-200, 100-190, 100-180, 100-170, 100-160, 140-170. 140-160, 150-170, or 150-160 nucleotides. In some embodiments, the promoter is at least about 100, 110, 120,Attorney Docket No.: 62801.89W001130, 140, 150, 160 nucleotides in length. In some embodiments, the promoter is about 100, 110, 120, 130, 140, 150, 160 nucleotides in length. In some embodiments, the promoter is no longer than about 200, 190. 180, 170, 165, or 160, nucleotides in length.4.3 Exemplary Properties of Promoters and Nucleic Acid Molecules Comprising the Same
[0021] In some embodiments, the inclusion of a promoter described herein in a DNA molecule enhances the rate of transcription of a DNA molecule (e.g., a coding region (open reading frame)) that is operably connected to the promoter (e.g., relative to the rate of transcription of the DNA molecule (e.g., the coding region (open reading frame)) operably connected to a reference promoter). In some embodiments, the inclusion of a promoter described herein in a DNA molecule enhances the rate of transcription of a DNA molecule (e.g., a coding region (open reading frame)) that is operably connected to the promoter relative to the rate of transcription of the DNA molecule (e.g., the coding region (open reading frame)) operably connected to a reference promoter.
[0022] In some embodiments, the inclusion of a promoter described herein in a DNA molecule enhances the rate of transcription of a DNA molecule (e.g., a coding region (open reading frame)) that is operably connected to the promoter relative to the rate of transcription of the DNA molecule (e.g., the coding region (open reading frame)) operably connected to a reference promoter described herein. In some embodiments, the inclusion of a promoter described herein in a DNA molecule enhances the rate of transcription of a DNA molecule (e.g., a coding region (open reading frame)) that is operably connected to the promoter relative to the rate of transcription of the DNA molecule (e.g., the coding region (open reading frame)) operably connected to a reference promoter comprising the nucleotide sequence set forth in SEQ ID NO: 9.
[0023] In some embodiments, the rate of transcription is enhanced by at least 1-fold, 2-fold, 5-fold, 10-fold, 20-fold, 30-fold, 40-fold, 50-fold, 100-fold, 500-fold, 1000-fold, 5000-fold, 10000-fold, 50000-fold, or 100000-fold.
[0024] The rate of transcription can measured by standard methods known in the art. For example, the rate of transcription can be assessed by measuring the amount of RNA transcript produced and / or the amount of protein produced in a cell. Such measurement can be compared to a reference promoter (e.g., whose transcriptional activity has been previously assessed). A reference promoter can be a known promoter that drives expression of a housekeeping gene. In certain embodiments, the reference promoter is one described herein (e.g., in Table 1). In certainAttorney Docket No.: 62801.89W001embodiments, the reference promoter comprises the nucleotide sequence set forth in SEQ ID NO: 9.4.4 DNA Molecules
[0025] Provided herein are DNA molecules comprising one or more promoter described herein (see, e.g., § 4.2).
[0026] In some embodiments, the DNA is a linear coding DNA construct. In some embodiments, the DNA contained within a vector e.g., a non-viral vector (e.g., a plasmid) or a viral vector). In some embodiments, the DNA is contained within a non-viral vector (e.g., a plasmid). In some embodiments, the DNA is contained within a viral vector (e.g., described herein). A more detailed description of vectors for both RNA and DNA nucleic acids is provided in § 4.8.4.4.1 Codon Optimization
[0027] In some embodiments, the sequence of a DNA molecule described herein is codon optimized, e.g., for expression in humans.
[0028] Codon optimization, in some embodiments, may be used to match codon frequencies in target and host organisms to ensure proper folding; bias guanosine (G) and / or cytosine (C) content to increase nucleic acid stability; minimize tandem repeat codons or base runs that may impair gene construction or expression; customize transcriptional and translational control regions; insert or remove protein trafficking sequences; remove / add post translation alteration sites in encoded protein (e.g. glycosylation sites); add, remove, or shuffle protein domains; insert or delete restriction sites; modify ribosome binding sites and mRNA degradation sites; adjust translational rates to allow the various domains of the protein to fold properly; or to reduce or eliminate problem secondary structures within the polynucleotide.
[0029] In some embodiments, the codon optimized DNA sequence shows one or more of the above (compared to a reference DNA sequence). In some embodiments, the codon optimized DNA sequence shows one or more of improved resistance to in vivo degradation, improved stability in vivo, reduced secondary structures, and / or improved translatability in vivo, compared to a reference DNA sequence. Codon optimization methods, tools, algorithms, and services are known in the art, non-limiting examples include services from GeneArt (Life Technologies) and DNA2.0 (MenloAttorney Docket No.: 62801.89W001Park Calif.). In some embodiments, the open reading frame (ORF) sequence is optimized using optimization algorithms. In some embodiments, the DNA sequence is modified or varied to optimize the number of G and / or C nucleotides as compared to a reference DNA sequence. An increase in the number of G and C nucleotides may be generated by substitution of codons containing adenosine (T) or thymidine (T) (or uracil (U)) nucleotides by codons containing G or C nucleotides.4.5 Regulatory Elements
[0030] The nucleic acid molecules (e.g., DNA molecules) described herein can comprise one or more regulatory elements (e.g., transcriptional regulatory elements), including, but not limited to, enhancers, introns, untranslated regions (UTRs), inverted terminal repeats, transcription termination sequences, posttranscriptional regulatory elements, and polyA signals.4.5.1 Enhancers
[0031] In some embodiments, a DNA molecule described herein comprises one or more enhancer. In some embodiments, the enhancer is positioned 5' of the promoter. In some embodiments, the enhancer is positioned 3' of the promoter. In some embodiments, a first enhancer is positioned 5' of the promoter and a second enhancer is positioned 3' of the promoter. In some embodiments, the DNA molecule comprises a plurality of enhancers.
[0032] In some embodiments, the enhancer is directly operably connected to the promoter. In some embodiments, the enhancer is indirectly operably connected to the promoter. Enhancers can be naturally occurring or engineered. Enhancers can be recombinantly or synthetically produced. Enhancers can be of e.g., mammalian, bacterial, or viral origin.
[0033] Enhancers suitable for use in the DNA molecules described herein are known in the art. Exemplary enhancers include, but are not limited to, CMV enhancer, SV40 enhancer GAPDH enhancer, p-actin enhancer, and EFl-a enhancer.
[0034] In some embodiments, the DNA molecule does not contain an enhancer.4.5.2 Introns
[0035] In some embodiments, a DNA molecule described herein comprises one or more intron. In some embodiments, the intron is a major intron, a minor intron, a hybrid intron, and / or a chimeric intron. In some embodiments, the intron is isolated or derived from a viral intron. In someAttorney Docket No.: 62801.89W001embodiments, the intron is isolated or derived from a mammalian intron. In some embodiments, the intron is isolated or derived from a human intron. In some embodiments, the intron is isolated or derived from an intronic sequence of one or more of SV40 (SV40IN), P-globin (e.g., human P-globin gene), chicken beta-actin, minute virus of mice (MVM), factor IX, and / or human IgG (heavy or light chain).
[0036] Introns can, e.g., enhance expression of a coding region (open reading frame) compared with expression of the coding region (open reading frame) in the absence of the intron; enhance the rate of transcription of a coding region (open reading frame) compared with rate of transcription of the coding region (open reading frame) in the absence of the intron; enhance nuclear export of a transcript compared with the nuclear export of the transcript in the absence of the intron; and / or enhance stability of a transcript compared with the stability of the transcript in the absence of the intron.
[0037] In some embodiments, inclusion of an intron enhances expression of a coding region (open reading frame) compared with expression of the coding region (open reading frame) in the absence of the intron. In some embodiments, inclusion of an intron enhances the rate of transcription of a coding region (open reading frame) compared with rate of transcription of the coding region (open reading frame) in the absence of the intron. In some embodiments, inclusion of an intron enhances nuclear export of a transcript compared with the nuclear export of the transcript in the absence of the intron. In some embodiments, inclusion of an intron enhances stability of a transcript compared with the stability of the transcript in the absence of the intron.4.5.3 Inverted Terminal Repeats (ITRs)
[0038] In some embodiments, a DNA molecule described herein comprises one or more inverted terminal repeat (ITR). In some embodiments, a DNA molecule described herein comprises a 5' ITR. In some embodiments, a DNA molecule described herein comprises a 3' ITR. In some embodiments, a DNA molecule described herein comprises a 5' ITR and a 3' ITR.
[0039] In some embodiments, the 5’ ITR is directly operably connected to the promoter. In some embodiments, the 5' ITR is directly operably connected to the 5' end of the promoter. In some embodiments, the 5' ITR is indirectly operably connected to the 5' end of the promoter. In some embodiments, the 3' ITR is directly operably connected to the open reading frame. In some embodiments, the 3' ITR is directly operably connected to the 3' end of the open reading frame. InAttorney Docket No.: 62801.89W001some embodiments, the 3' ITR is indirectly operably connected to the 3' end of the open reading frame.4.5.4 Untranslated Regions (UTRs)
[0040] In some embodiments, a DNA molecule described herein comprises one or more untranslated region. In some embodiments, a DNA molecule described herein comprises one or more 5' UTR. In some embodiments, a DNA molecule described herein comprises one or more 3' UTR. In some embodiments, a DNA molecule described herein comprises one or more 5' UTR and one or more 3' UTR. The 5' UTR and / or the 3' UTR can contain one or more other transcription regulatory elements (e.g., described herein). For example, a 3' UTR may contain a posttranscriptional regulatory element described herein; a 5' UTR may contain an intron (e.g., described herein).
[0041] In some embodiments, the 5' UTR is positioned between the promoter and an open reading frame. In some embodiments, the 5' UTR is directly operably connected to the promoter. In some embodiments, the 5' UTR is directly operably connected to the 5' end of the promoter. In some embodiments, the 5' UTR is indirectly operably connected to the 5’ end of the promoter. In some embodiments, the 5' UTR is directly operably connected to the 3' end of the promoter. In some embodiments, the 5' UTR is indirectly operably connected to the 3' end of the promoter. In some embodiments, the 3' UTR is directly operably connected to the open reading frame. In some embodiments, the 3' UTR is directly operably connected to the 3' end of the open reading frame. In some embodiments, the 3' UTR is indirectly operably connected to the 3' end of the open reading frame.4.5.5 Transcription Termination Sequence
[0042] In some embodiments, a DNA molecule described herein comprises a transcription termination sequence. In some embodiments, the transcription termination sequence is operably connected to the 3' end of an open reading frame. In some embodiments, the transcription termination sequence is directly operably connected to the 3' end of an open reading frame. In some embodiments, the transcription termination sequence is indirectly operably connected to the 3' end of an open reading frame.
[0043] In some embodiments, the transcription termination sequence comprises a poly(A)Attorney Docket No.: 62801.89W001signal sequence (e.g., described herein). In some embodiments, the transcription termination sequence consists of a poly(A) signal sequence (e.g., described herein). Other transcription terminational sequences that can function in a variety of host cells are known in the art. See, e.g., Zhang, Huimin et al. “Poly(A) Signal-Dependent Transcription Termination Occurs through a Conformational Change Mechanism that Does Not Require Cleavage at the Poly(A) Site.” Molecular cell vol. 59,3 (2015): 437-48. doi:10.1016 / j.molcel.2015.06.008 (and references cited therein), the entire contents of which are incorporated herein by reference for all purposes.4.5.6 Posttranscriptional Regulatory Elements (PREs)
[0044] In some embodiments, a DNA molecule described herein comprises one or more posttranscriptional regulatory elements (PREs). In some embodiments, the PRE is operably connected to the 3' end of an open reading frame. In some embodiments, the PRE is directly operably connected to the 3' end of an open reading frame. In some embodiments, the PRE is indirectly operably connected to the 3' end of an open reading frame.
[0045] In some embodiments, the PRE is derived from a virus. In some embodiments, the PRE is derived from a hepatitis virus. Exemplary, PREs include, but are not limited to, woodchuck hepatitis virus posttranscriptional regulatory' element (WPRE), hepatitis B virus posttranscriptional regulatory element (HPRE). See, e.g., Mouzannar, K.; Schauer, A.; Liang, T.J. The Post-Transcriptional Regulatory Element of Hepatitis B Virus: From Discovery to Therapy. Viruses 2024, 16, 528. https: / / doi.org / 10.3390 / vl6040528, the entire contents of which are incorporated herein by reference for all purposes.4.5.7 Poly(A) Signal Sequence
[0046] In some embodiments, a DNA molecule described herein comprises a poly(A) signal sequence. In some embodiments, the poly(A) signal sequence functions as a transcription termination sequence. In some embodiments, the poly(A) signal sequence is operably connected to the 3' end of an open reading frame. In some embodiments, the poly(A) signal sequence is directly operably connected to the 3' end of an open reading frame. In some embodiments, the poly(A) signal sequence is indirectly operably connected to the 3' end of an open reading frame.
[0047] Exemplary poly(A) signal sequences include, but are not limited to, a rabbit -globin poly A signal, a human growth hormone (hGH) polyA signal, a SV40 late poly A signal, a syntheticAttorney Docket No.: 62801.89W001polyA (SPA) signal, or a bovine growth hormone (bGH) polyA signal. See, e.g., Powell and Rivera-Soto, 2015, Discov. Med., 19(102)149-57, the entire contents of which are incorporated herein by reference for all purposes.4.6 Open Reading Frames
[0048] As described elsewhere, nucleic acid molecules described herein (e.g., DNA molecules) encode one or more proteins or RNA transcripts, nucleic acid molecules described herein (e.g., DNA molecules) encode one or more proteins, nucleic acid molecules described herein (e.g., DNA molecules) encode one or more RNA transcripts.
[0049] As described elsewhere, in preferred embodiments, nucleic acid molecules described herein (e.g., RNA molecules) comprise one or more open reading frames. In some embodiments, the one or more open reading frame encodes a protein (e.g., a therapeutic protein) described herein, e.g., § 4.6.1. In some embodiments , the one or more open reading frame encodes a therapeutic protein described herein, e.g., § 4.6.1.
[0001] In some embodiments, the nucleic acid molecule (e.g., RNA molecule) comprises at least one open reading frame. In some embodiments, the nucleic acid molecule (e.g., RNA molecule) comprises at least 1, 2, 3, 4, 5, or 6, or more open reading frames. In some embodiments, the nucleic acid molecule (e.g., RNA molecule) comprises 1. 2, 3, 4, 5, or 6, or more open reading frames. In some embodiments, each open reading frame encodes a different protein. In some embodiments, each open reading frame is separated by a stagger element (e.g., described herein). In some embodiments, each open reading frame encodes a different RNA transcript.4.6.1 Proteins (e.g., Therapeutic Proteins)
[0002] As described herein, in some embodiments, a DNA molecule described herein encodes one or more protein. In some embodiments, the protein is a therapeutic protein.
[0003] In some embodiments, the therapeutic protein is a secreted protein, an intracellular protein (e.g., an enzyme), or a membrane protein (e.g., a transmembrane protein). In some embodiments, the membrane protein is a transmembrane protein. In some embodiments, the therapeutic protein is an antibody, an enzyme, a cytokine, a chemokine, a hormone, a growth factor, a fusion protein (e.g., an antibody cytokine fusion protein), or an immunogen, or a functional fragment or functional variant of any of the foregoing. In some embodiments, theAttorney Docket No.: 62801.89W001therapeutic protein is an immunogenic protein, e.g., a vaccine, part of a vaccine.
[0004] In some embodiments, the therapeutic protein is an antibody. In some embodiments, the therapeutic protein is an enzyme. In some embodiments, the therapeutic protein is a cytokine. In some embodiments, the therapeutic protein is a chemokine. In some embodiments, the therapeutic protein is a hormone. In some embodiments, the therapeutic protein is a growth factor. In some embodiments, the therapeutic protein is a fusion protein (e.g., an antibody cytokine fusion protein). In some embodiments, the therapeutic protein is an immunogen.
[0005] In some embodiments, the therapeutic protein is an immune cell inhibitor (e.g., a T cell inhibitor, a B cell, an NK cell inhibitor, a T regulatory cell inhibitor, a Th 17 cell inhibitor, a dendritic cell inhibitor, a macrophage inhibitor). In some embodiments, the therapeutic protein is a cytokine inhibitor. In some embodiments, the therapeutic protein is a chemokine inhibitor. In some embodiments, the therapeutic protein is an interleukin inhibitor.
[0006] In some embodiments, the therapeutic protein is an IL-1, IL-2, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, -IL9, IL-10, IL-11, IL-12, IL-13, IL-14. IL-15. IL-16, IL-17, IL-18, IL-19, IL-20, IL-21, IL-22, IL-23, IL-24, IL-25, IL-26, IL-27, IL-28, IL-29, IL-30, IL-31, IL-32, IL-33, IL-34, IL-35, IL-36, IL-37, IL-38, IL-39, and / or IL-40 inhibitor. In some embodiments, the therapeutic protein is an IFNa, IFNp, IFNy, TNFa, TNF0, LT-0, cd!54, GMCSF, GCSF, CSIF, MCSF, MSP, SCF, NGF, MCP-1, LIF, OSM, 4-1BBL, APRIL, CD70, CD153, CD178, GITRL, LIGHT, OX40L, TALL-1, TRAIL, TWEAK, TRANCE, TGFpi, TGFp2, TGFp3, Flts-3L, TPO, EPO, CCL1, CCL2, CCL3, CCL4, CCL5, CCL6, CCL7, CCL8, CCL9, CCL10, CCL11, CCL12, CCL13, CCL14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL1, CCL20, CCL21, CCL22, CCL23, CCL24. CCL25, CCL26, CCL27, CCL28. CXCL1. CXCL2. CXCL3. CXCL4, CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL15, CXCL16. CCR1, CCR2, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9. CCR10, CXCR1, CXCR2, CXCR3, CXCR4. CXCR5. or CXCR6 inhibitor.
[0007] Exemplary therapeutic proteins include, but are not limited to, abatacept, adalimumab, adalimumab-atto, certolizumab, certolizumab pegol, etanercept, etanercept-szzs, golimumab, golimumab injection, infliximab, infliximab-dyyb, secukinumab, tocilizumab, ustekinumab, anakinra, canakinumab, rituximab, tocilizumab, interferon beta- lb, daclizumab, interferon betala, natalizumab, interferon beta- la, peginterferon beta- la, ixekizumab. brodalumab, bimekizumab, tildrakizumab, tildrakizumab-asmn, risankizumab, guselkumab, rilonacept,Attorney Docket No.: 62801.89W001belimumab, interferon gamma- lb, abciximab, alteplase, reteplase, tenecteplase, abobotulinum toxin a, onabotulinum toxin a, incobotulinum toxin a, anakinra, rimabotulinum toxin b, follitropin alpha, abobotulinum toxin a, onabotulinum toxin a. collagenase, ecallantide. collagenase Clostridium histolyticum, aflibercept, ziv-aflibercept, ranibizumab, ocriplasmin, bevacizumab, pegaptanib, interferon alfa-2b, obinutuzumab, asparaginase, asparaginase erwinia chrysanthemi, blinatumomab. interferon alfa-2b, obinutuzumab, ofatumumab, pegaspargase, sargramostim, nivolumab, brentuximab vedotin, ibritumomab tiuxetan, rituximab, ado-trastuzumab emtansine, pertuzumab, trastuzumab, aldesleukin, daratumumab, elotuzumab, pembrolizumab, ipilimumab, atezolizumab, cetuximab, atezolizumab, necitumumab, ramucirumab, panitumumab, capromab pendetide, olaratumab, elosulfase alfa, idursulfase, iaronidase, asfotase alfa, pegloticase, alirocumab, evolocumab. albiglutide, dulaglutide. becaplermin, agalsidase beta, alglucosidase alfa, canakinumab, galsulfase, metreleptin, rasburicase, sebelipase alfa, parathyroid hormone, bezlotoxumab, interferon alfa-2b, interferon alfa-n3, peginterferon alfa-2a, peginterferon alfa-2b, palivizumab. siltuximab, pegfilgrastim, sargramostim, epoetin alfa, methoxy polyethylene glycol-epoetin beta, basiliximab, belatacept, sargramostim, palifermin, eculizumab, oprelvekin, romiplostim, glucarpidase, idarucizumab, obiltoxaximab, raxibacumab, domase alfa, mepolizumab, reslizumab, and omalizumab.
[0008] A list of exemplary therapeutic proteins are provided in Table 3 below. The therapeutic proteins listed in Table 3 are exemplary and not intended to be limiting.Table 3. Exemplary Therapeutic Proteins.Description Exemplary Indication(s)Abatacept ArthritisPsoriatic ArthritisAdalimumab ArthritisAnkylosing SpondylitisPsoriasisPsoriatic ArthritisCrohn’s DiseaseUlcerative ColitisAdalimumab-Atto ArthritisAnkylosing SpondylitisPsoriasisPsoriatic ArthritisCrohn’s DiseaseUlcerative ColitisCertolizumab Psoriatic ArthritisCertolizumab Pegol ArthritisAnkylosing SpondylitisAttorney Docket No.: 62801.89W001Psoriatic ArthritisEtanercept ArthritisAnkylosing SpondylitisPsoriatic ArthritisEtanercept-Szzs ArthritisAnkylosing SpondylitisPsoriatic ArthritisGolimumab ArthritisAnkylosing SpondylitisUlcerative ColitisGolimumab Injection ArthritisAnkylosing SpondylitisUlcerative ColitisInfliximab ArthritisAnkylosing SpondylitisPsoriasisPsoriatic ArthritisCrohn’s DiseaseUlcerative ColitisInfliximab-Dyyb ArthritisAnkylosing SpondylitisPsoriasisPsoriatic ArthritisCrohn’s DiseaseUlcerative ColitisSecukinumab ArthritisAnkylosing SpondylitisPsoriasisPsoriatic ArthritisTocilizumab ArthritisUstekinumab ArthritisPsoriasisPsoriatic ArthritisCrohn’s DiseaseAnakinra ArthritisCanakinumab ArthritisRituximab ArthritisTocilizumab ArthritisInterferon Beta- lb Multiple SclerosisDaclizumab Multiple SclerosisInterferon Beta- la Multiple SclerosisNatalizumab Multiple SclerosisInterferon Beta- la Multiple SclerosisPeginterferon Beta- la Multiple SclerosisIxekizumab PsoriasisPsoriatic ArthritisBrodalumab PsoriasisPsoriatic ArthritisBimekizumab Psoriatic ArthritisTildrakizumab Psoriatic ArthritisAttorney Docket No.: 62801.89W001Tildrakizumab-Asmn Psoriatic ArthritisRisankizumab Psoriatic ArthritisGuselkumab Psoriatic ArthritisRilonacept PericarditisCryopyrin-Associated Periodic SyndromesBelimumab Systemic Lupus ErythematosusInterferon Gamma- lb Chronic Granulomatous DiseaseAbciximab Myocardial IschemiaAlteplase Myocardial InfarctionReteplase Myocardial InfarctionTenecteplase Myocardial InfarctionAbobotulinum Toxin A Neurological ConditionsOnabotulinum Toxin A Neurological ConditionsIncobotulinum Toxin A Neurological ConditionsAnakinra Neurological ConditionsRimabotulinum Toxin B Neurological ConditionsFollitropin Alpha Neurological ConditionsAbobotulinum Toxin A Dermatological ConditionsOnabotulinum Toxin A Dermatological ConditionsCollagenase Dermatological ConditionsEcallantide Dermatological ConditionsIncobotulinum Toxin A Dermatological ConditionsCollagenase Clostridium Histolyticum Dermatological ConditionsAflibercept Eye Conditions; Cancer (e.g., Colorectal)Ziv-Aflibercept Eye Conditions; Cancer (e.g., Colorectal)Ranibizumab Eye ConditionsIncobotulinum Toxin A Eye ConditionsOcriplasmin Eye ConditionsBevacizumab Eye Conditions; Cancer (e.g., Colorectal)Pegaptanib Eye ConditionsInterferon Alfa-2b Cancer (e.g., Leukemia, Lymphoma)Obinutuzumab Cancer (e.g., Leukemia)Asparaginase Cancer (e.g., Leukemia)Asparaginase Erwinia Chrysanthemi Cancer (e.g., Leukemia)Blinatumomab Cancer (e.g., Leukemia)Interferon Alfa-2b Cancer (e.g., Leukemia, Lymphoma, Skin (e.g., Melanoma)) Obinutuzumab Cancer (e.g., Leukemia, Lymphoma)Ofatumumab Cancer (e.g., Leukemia)Pegaspargase Cancer (e.g., Leukemia)Sargramostim Cancer (e.g., Leukemia)Nivolumab Cancer (e.g., Lymphoma, Skin (e.g., Melanoma), Carcinoma,Lung)Brentuximab Vedotin Cancer (e.g., Lymphoma)Ibritumomab Tiuxetan Cancer (e.g., Lymphoma)Rituximab Cancer (e.g., Lymphoma)Ado-Trastuzumab Emtansine Cancer (e.g., Breast)Pertuzumab Cancer (e.g., Breast)Trastuzumab Cancer (e.g., Breast, Gastric)Aldesleukin Cancer (e.g., Skin, (e.g., Melanoma), Carcinoma)Attorney Docket No.: 62801.89W001Daratumumab Cancer (e.g., Skin, e.g., Melanoma)Elotuzumab Cancer (e.g., Skin, e.g., Melanoma)Pembrolizumab Cancer (e.g., Skin, (e.g., Melanoma), Lung)Ipilimumab Cancer (e.g., Skin, (e.g., Melanoma), Carcinoma) Atezolizumab Cancer (e.g., Carcinoma, Lung)Cetuximab Cancer (e.g., Carcinoma, Colorectal)Atezolizumab Cancer (e.g., Lung)Necitumumab Cancer (e.g., Lung)Ramucirumab Cancer (e.g., Lung, Colorectal, Gastric)Panitumumab Cancer (e.g., Colorectal)Capromab Pendetide Cancer (e.g., Prostate)Olaratumab Cancer (e.g., Solid Tumors)Elosulfase Alfa Mucopol y sacchari dosi sIdursulfase MucopolysaccharidosisTaronidase Mucopol y sacchari dosi sAsfotase Alfa HypophosphatasiaPegloticase GoutAlirocumab HypercholesterolemiaEvolocumab HypercholesterolemiaAlbiglutide DiabetesDulaglutide DiabetesBecaplermin DiabetesAgalsidase Beta Fabry diseaseAlglucosidase Alfa Pompe diseaseCryopyrin-Associated Periodic Syndromes; Systemic CanakinumabJuvenile Idiopathic ArthritisGalsulfase Mucopolysaccharidosis VIMetreleptin LipodystrophyRasburicase HyperuricemiaSebelipase Alfa Lysosomal Acid Lipase DeficiencyParathyroid Hormone HypocalcemiaBezlotoxumab Infection (e.g., Bacterial)Interferon Alfa-2b Infection (e.g., Viral)Interferon Alfa-N3 Infection (e.g., Viral)Peginterferon Alfa-2a Infection (e.g., Viral)Peginterferon Alfa-2b Infection (e.g., Viral)Palivizumab Infection (e.g., Viral)Siltuximab Infection (e.g., Viral)Pegfilgrastim NeutropeniaSargramostim NeutropeniaEpoetin Alfa AnemiaMedtoxy Polyediylene Glycol-Epoetin AnemiaBetaBasiliximab Transplant RejectionBelatacept Transplant RejectionSargramostim Transplant RejectionPalifermin Transplant RejectionEculizumab Paroxysmal Nocturnal Hemoglobinuria; Atypical HemolyticUremic SyndromeAttorney Docket No.: 62801.89W001Oprelvekin ThrombocytopeniaRomiplostim ThrombocytopeniaGlucarpidase Methotrexate ToxicityIdarucizumab Dabigatran ReversalObiltoxaximab Inhalational AnthraxRaxibacumab Inhalational AnthraxDornase Alfa Cystic FibrosisMepolizumab Eosinophilic AsthmaReslizumab Eosinophilic AsthmaOmalizumab Eosinophilic Asthma
[0009] In some embodiments, the therapeutic protein is a therapeutic protein listed in Table 3. In some embodiments, the therapeutic protein comprises a therapeutic protein listed in Table 3. In some embodiments, the therapeutic protein consists of a therapeutic protein listed in Table 3.
[0010] In some embodiments, the therapeutic protein can be used treat a disease. In some embodiments, the therapeutic protein can be used treat a proinflammatory disease, an autoimmune disease, an infection, a cancer, a neurological condition, an eye condition, a dermatological condition, transplant rejection, a blood disorder, a cardiovascular disease, a metabolic disease, bone disease, an endocrine disease, a genetic disease, a lipid disease, a uric acid disease, a calcium disease, or a drug toxicity.
[0011] Exemplary pro-inflammatory diseases include, but are not limited to, arthritis, rheumatoid arthritis, psoriasis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, multiple sclerosis, pericarditis, cryopyrin-associated periodic syndromes, systemic lupus erythematosus, chronic granulomatous disease, gout, systemic juvenile idiopathic arthritis, transplant rejection, diabetes, asthma, and eosinophilic asthma.
[0012] Exemplary autoimmune diseases include, but are not limited to, multiple sclerosis, Crohn’s disease, ulcerative colitis, systemic lupus erythematosus, diabetes, rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, arthritis, autoimmune pericarditis, Cryopyrin-associated autoinflammatory syndromes (CAPS), and autoimmune diabetes mellitus.
[0013] Cancers include, e.g., solid tumors and liquid cancers. Exemplary cancers include, but are not limited to, colon cancer, rectal cancer, colorectal cancer, skin cancer (e.g., melanoma), lung cancer, breast cancer, gastric cancer, leukemia, and lymphoma. Exemplary metabolic diseases include, but are not limited to, mucopolysaccharidosis.
[0014] Exemplary cardiovascular diseases include, but are not limited to, myocardial ischemia, myocardial infarction, and hypercholesterolemia. Exemplary bone diseases include, butAttorney Docket No.: 62801.89W001are not limited to, hypophosphatasia. Exemplary endocrine diseases include, but are not limited to, diabetes. Exemplary neurological diseases include, but are not limited to, Fabry disease. Exemplary genetic disease include, but are not limited, to, Pompe disease, mucopolysaccharidosis VI, lysosomal acid lipase deficiency, atypical hemolytic uremic syndrome, cystic fibrosis, and Fabry disease. Exemplary lipid diseases include, but are not limited to, lipodystrophy, and cystic fibrosis, Exemplary uric acid diseases include, but are not limited to, hyperuricemia. Exemplary calcium diseases include, but are not limited to, hypocalcemia. Exemplary infections include, but are not limited to, viral infections, bacterial infections, parasite infections, yeast infections, and fungal infections. Exemplary blood disorders include, but are not limited to, neutropenia, anemia, paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and thrombocytopenia. Exemplary drug toxicities include, but are not limited to, methotrexate toxicity and dabigatran toxicity.4.6.2 RNA Transcripts
[0015] As described elsewhere, in some embodiments nucleic acid molecules described herein (e.g., DNA molecules) comprise one or more open reading frames. In some embodiments, the one or more open reading frame encodes an RNA transcript. In some embodiments , the one or more open reading frame encodes a therapeutic RNA transcript.
[0016] Exemplary RNA transcripts include, but are not limited to, tRNA, miRNA, siRNA, antisense oligonucleotides (ASO), IncRNA, rRNA, snRNA, microRNA, piRNA, snoRNA, snRNA, exRNA, scaRNA, Y RNA, or hnRNA. In some embodiments, the DNA molecule encodes a regulatory RNA molecule. In some embodiments, the DNA molecule encodes a tRNA, miRNA, siRNA, ASO, IncRNA, rRNA, snRNA, microRNA, piRNA, snoRNA, snRNA, exRNA, scaRNA, Y RNA, or hnRNA.4.7 Methods of Making Nucleic Acid Molecules
[0017] Nucleic acid molecules described herein can be generated using common methods known in the art (e.g., chemical synthesis). For example, DNA molecules described herein can be generated using variations of the phosphoramidite chemistry methods on column-based synthesizers or microarray-based synthesizers. See, e.g., Hughes RA, Ellington AD. Synthetic DNA Synthesis and Assembly: Putting the Synthetic in Synthetic Biology. Cold Spring HarbAttorney Docket No.: 62801.89W001Perspect Biol. 2017 Jan 3;9( 1 ):a023812. doi: 10.1101 / cshperspect.a023812. PMID: 28049645; PMCID: PMC5204324; Hoose, A., Vellacott, R., Storch, M. et al. DNA synthesis technologies to close the gene writing gap. Nat Rev Chem 7, 144-161 (2023). https: / / doi.org / 10.1038 / s41570-022-00456-9; and Kosuri, S., Church, G. Large-scale de novo DNA synthesis: technologies and applications. Nat Methods 11, 499-507 (2014). https: / / doi.org / 10.1038 / nmeth.2918; the entire contents of each of which is incorporated herein by reference for all purposes.4.8 Vectors
[0018] In some embodiments, a promoter described herein, a nucleic acid molecule described herein (e.g., a DNA molecule) is contained in a vector (e.g., a non-viral vector, a viral vector). Thus, also provided herein are, inter alia, vectors (e.g., viral vectors, non-viral vectors (e.g., plasmids, minicircles)) comprising one or more promoter described herein or nucleic acid molecule described herein. Such vectors can be easily manipulated by methods well known to the ordinary person of skill in the art.
[0019] In some embodiments, the vector is a non-viral vector (e.g., a plasmid, minicircle). In some embodiments, the vector is a plasmid. A person of ordinary skill in the art is aware of suitable plasmids for expression of the DNA of interest. For example, Suitable plasmid DNA may be generated to allow efficient production of the encoded peptides or proteins (e.g., SARS-CoV-2 proteins or polypeptides (e.g., immunogens) in cell lines, e.g., in insect cell lines, for example using vectors as described in W02009150222A2 and as defined in PCT claims 1 to 33, the disclosure relating to claim 1 to 33 of W02009150222A2 the entire contents of which is incorporated by reference herein for all purposes.
[0020] In some embodiments, the vector is a viral vector. Viral vectors include both RNA and DNA based vectors. The vectors can be designed to meet a variety of specifications. For example, viral vectors can be engineered to be capable or incapable of replication in prokaryotic and / or eukaryotic cells. In some embodiments, the vector is replication deficient. In some embodiments, the vector is replication competent. Viral vectors can be engineered or selected that either will (or will not) integrate in whole or in part into the genome of host cells, resulting (or not (e.g., episomal expression)) in stable host cells comprising the desired nucleic acid in their genome.
[0021] Exemplary viral vectors include, but are not limited to, adenovirus vectors, adeno-associated virus vectors, lentivirus vectors, retrovirus vectors, poxvirus vectors, parapoxivirusAttorney Docket No.: 62801.89W001vectors, vaccinia virus vectors, fowlpox virus vectors, herpes virus vectors, adeno-associated virus vectors, alphavirus vectors, lentivirus vectors, rhabdovirus vectors, measles virus, Newcastle disease virus vectors, picomaviruses vectors, or lymphocytic choriomeningitis virus vectors. In some embodiments, the viral vector is an adenovirus vector, adeno-associated virus vector, or a lentivirus vector.
[0022] In some embodiments, the vector is an adenovirus vector (e.g., a human adenoviral vector, e.g., HAdV or AdHu). In some embodiments, the adenovirus vector has the El region deleted, rendering it replication-deficient in human cells. Other regions of the adenovirus such as E3 and E4 may also be deleted. Exemplary adenovirus vectors include, but are not limited to, those described in e.g., W02005071093 or WQ2006048215, the entire contents of each of which is incorporated herein by reference for all purposes. In some embodiments, the adenovirus-based vector used is a simian adenovirus, thereby avoiding dampening of the immune response after vaccination by pre-existing antibodies to common human entities such as AdHu5. Exemplary, simian adenovirus vectors include AdCh63 {see, e.g., W02005071093. the entire contents of which is incorporated herein by reference for all purposes) or AdCh68.
[0023] Viral vectors can be generated through the use of a packaging / producer cell line (e.g., a mammalian cell line) using standard methods known to the person of ordinary skill in the art. Generally, a nucleic acid construct (e.g., a plasmid) encoding the peptide or protein of interest (along with additional elements e.g., a promoter, inverted terminal repeats (ITRs) flanking the transgene, a plasmid encoding e.g., viral replication and structural proteins, along with one or more helper plasmids a host cell (e.g., a host cell line) are transfected into a host cell line (i.e., the packing / producer cell line). In some instances, depending on the viral vector, a helper plasmid may also be needed that include helper genes from another virus (e.g., in the instance of adeno-associated viral vectors). Eukaryotic expression plasmids are commercially available from a variety of suppliers, for example the plasmid series: pcDNA™, pCR3.1 ™. pCMV™. pFRT™, pVAXl ™, pCI™, Nanoplasmid™, and Pcaggs. The person of ordinary skill in the art is aware of numerous transfection methods and any suitable method of transfection may be employed (e.g., using a biochemical substance as carrier (e.g., lipofectamine), by mechanical means, by electroporation). The cells are cultured under conditions suitable and for a sufficient time for plasmid expression. The viral particles may be purified from the cell culture medium using standard methods known to the person of ordinary skill in the art. For example, by centrifugationAttorney Docket No.: 62801.89W001followed by e.g., chromatography and / or ultrafiltration.4.9 Carriers
[0024] In some embodiments, one or more agent described herein, including, one or more of a promoter described herein, a nucleic acid molecule described herein (e.g., a DNA molecule described herein), a protein (e.g., therapeutic protein) made by a method described herein, a vector described herein, a carrier described herein, a vaccine composition described herein, and / or a pharmaceutical composition described herein is formulated within one or more carrier.
[0025] Therefore, further provided herein are earners comprising any one or more of an agent described herein, e.g., a promoter described herein, a nucleic acid molecule described herein (e.g., a DNA molecule described herein), a protein (e.g., therapeutic protein) made by a method described herein, a vector described herein, a carrier described herein, a vaccine composition described herein, and / or a pharmaceutical composition described herein.
[0026] Any of the foregoing (e.g., one or more of a promoter described herein, a nucleic acid molecule described herein (e.g., a DNA molecule described herein), a protein (e.g., therapeutic protein) made by a method described herein, a vector described herein, a carrier described herein, a vaccine composition described herein, and / or a pharmaceutical composition described herein) can be encapsulated within a carrier, chemically conjugated to a earner, associated with the carrier. In this context, the term “associated” refers to the essentially stable combination of an agent described herein with one or more molecules of a carrier (e.g., one or more lipids of a lipid-based carrier, e.g., an LNP, liposome, lipoplex, and / or nanoliposome) into larger complexes or assemblies without covalent binding. In this context, the term “encapsulation” refers to the incorporation of one or more of an agent described herein, e.g., a promoter described herein, a nucleic acid molecule described herein (e.g., a DNA molecule described herein), a protein (e.g., therapeutic protein) made by a method described herein, a vector described herein, a carrier described herein, a vaccine composition described herein, and / or a pharmaceutical composition described herein into a carrier (e.g., a lipid-based carrier, e.g., an LNP, liposome, lipoplex, and / or nanoliposome) wherein the agent (e.g., a promoter described herein, a nucleic acid molecule described herein (e.g., a DNA molecule described herein), a protein (e.g., therapeutic protein) made by a method described herein, a vector described herein, a carrier described herein, a vaccine composition described herein, and / or a pharmaceutical composition described herein) is entirelyAttorney Docket No.: 62801.89W001contained within the interior space of the carrier (e.g., the lipid-based carrier, e.g., the LNP, liposome, lipoplex, and / or nanoliposome).
[0027] Exemplary carriers includes, but are not limited to, lipid-based carriers (e.g., lipid nanoparticles (LNPs), liposomes, lipoplexes, and nanoliposomes). In some embodiments, the carrier is a lipid-based carrier. In some embodiments, the carrier is an LNP. In some embodiments, the LNP comprises a cationic lipid, a neutral lipid, a cholesterol, and / or a PEG lipid. Lipid based carriers are further described below in § 4.9.1.4.9.1 Lipid Based Carriers / Lipid Nanoformulations
[0028] In some embodiments, one or more of an agent described herein (e.g., a promoter described herein, a nucleic acid molecule described herein (e.g., a DNA molecule described herein), a protein (e.g., therapeutic protein) made by a method described herein, a vector described herein, a carrier described herein, a vaccine composition described herein, and / or a pharmaceutical composition described herein) is encapsulated or associated with one or more lipids (e.g., cationic lipids and / or neutral lipids), thereby forming lipid-based carriers such as lipid nanoparticles (LNPs), liposomes, lipoplexes, or nanoliposomes.
[0029] In some embodiments, an agent described herein (e.g., a promoter described herein, a nucleic acid molecule described herein (e.g., a DNA molecule described herein), a protein (e.g., therapeutic protein) made by a method described herein, a vector described herein, a carrier described herein, a vaccine composition described herein, and / or a pharmaceutical composition described herein) is encapsulated in one or more lipids (e.g., cationic lipids and / or neutral lipids), thereby forming lipid-based carriers such as lipid nanoparticles (LNPs), liposomes, lipoplexes, or nanoliposomes. In some embodiments, an agent described herein (e.g., a promoter described herein, a nucleic acid molecule described herein (e.g., a DNA molecule described herein), a protein (e.g., therapeutic protein) made by a method described herein, a vector described herein, a carrier described herein, a vaccine composition described herein, and / or a pharmaceutical composition described herein) is associated with one or more lipids (e.g., cationic lipids and / or neutral lipids), thereby forming lipid-based carriers such as lipid nanoparticles (LNPs), liposomes, lipoplexes, or nanoliposomes. In some embodiments, an agent described herein (e.g., a promoter described herein, a nucleic acid molecule described herein (e.g., a DNA molecule described herein), a protein (e.g., therapeutic protein) made by a method described herein, a vector described herein, a carrierAttorney Docket No.: 62801.89W001described herein, a vaccine composition described herein, and / or a pharmaceutical composition described herein) is encapsulated in LNPs (e.g., as described herein).
[0030] The agent (e.g., promoter, a nucleic acid molecule described herein (e.g., a DNA molecule described herein), protein (e.g., therapeutic protein), vector, carrier, vaccine composition, and / or pharmaceutical composition) may be completely or partially located in the interior space of the LNPs, liposomes, lipoplexes, and / or nanoliposomes, within the lipid layer / membrane, or associated with the exterior surface of the lipid layer / membrane. One purpose of incorporating an agent (e.g., promoter, a nucleic acid molecule described herein (e.g., a DNA molecule described herein), protein (e.g., therapeutic protein), vector, carrier, vaccine composition, and / or pharmaceutical composition) into LNPs, liposomes, lipoplexes, and / or nanoliposomes is to protect the agent from an environment which may contain enzymes or chemicals or conditions that degrade the agent from molecules or conditions that cause the rapid excretion of the agent. Moreover, incorporating an agent (e.g., promoter, 3' UTR, nucleic acid molecule (e.g., DNA molecule)), protein (e.g., therapeutic protein), vector, carrier, vaccine composition, and / or pharmaceutical composition) into LNPs, liposomes, lipoplexes, and / or nanoliposomes may promote the uptake of the agent, and hence, may enhance the therapeutic effect of the agent (e.g., promoter, a nucleic acid molecule described herein (e.g., a DNA molecule described herein), protein (e.g., therapeutic protein), vector, carrier, vaccine composition, and / or pharmaceutical composition). Accordingly, incorporating an agent (e.g., promoter, a nucleic acid molecule described herein (e.g., a DNA molecule described herein), protein (e.g., therapeutic protein), vector, carrier, vaccine composition, and / or pharmaceutical composition), into LNPs, liposomes, lipoplexes, and / or nanoliposomes may be particularly suitable for a pharmaceutical composition described herein, e.g., for intramuscular and / or intradermal administration.
[0031] In some embodiments, an agent described herein (e.g., promoter, a nucleic acid molecule described herein (e.g., a DNA molecule described herein), protein (e.g., therapeutic protein), vector, carrier, vaccine composition, and / or pharmaceutical composition) is formulated into a lipid-based carrier (or lipid nanoformulation). In some embodiments, the lipid-based carrier (or lipid nanoformulation) is a liposome or a lipid nanoparticle (LNP). In one embodiment, the lipid-based carrier is an LNP.
[0032] In some embodiments, the lipid-based carrier (or lipid nanoformulation) comprises a cationic lipid (e.g., an ionizable lipid), a non-cationic lipid (e.g., phospholipid), a structural lipidAttorney Docket No.: 62801.89W001(e.g., cholesterol), and a PEG-modified lipid. In some embodiments, the lipid-based carrier (or lipid nanoformulation) contains one or more agent (e.g., promoter, a nucleic acid molecule described herein (e.g., a DNA molecule described herein), protein (e.g., therapeutic protein), vector, carrier, vaccine composition, and / or pharmaceutical composition), or a pharmaceutically acceptable salt thereof.
[0033] As described herein, suitable compounds to be used in the lipid-based carrier (or lipid nanoformulation) include all the isomers and isotopes of the compounds described above, as well as all the pharmaceutically acceptable salts, solvates, or hydrates thereof, and all crystal forms, crystal form mixtures, and anhydrides or hydrates.
[0034] In addition to the one or more agent described herein (e.g., promoter, a nucleic acid molecule described herein (e.g., a DNA molecule described herein), protein (e.g., therapeutic protein), vector, carrier, vaccine composition, and / or pharmaceutical composition), the lipid-based carrier (or lipid nanoformulation) may further include a second lipid. In some embodiments, the second lipid is a cationic lipid, a non-cationic (e.g., neutral, anionic, or zwitterionic) lipid, or an ionizable lipid.
[0035] One or more naturally occurring and / or synthetic lipid compounds may be used in the preparation of the lipid-based carrier (or lipid nanoformulation).
[0036] The lipid-based carrier (or lipid nanoformulation) may contain positively charged (cationic) lipids, neutral lipids, negatively charged (anionic) lipids, or a combination thereof.4.9.1.1 Cationic Lipids (Positively Charged) and Ionizable Lipids
[0037] In some embodiments, the lipid-based carrier (or lipid nanoformulation) comprises one or more cationic lipids, e.g., a cationic lipid that can exist in a positively charged or neutral form depending on pH, or an amine-containing lipid that can be readily protonated. In some embodiments, the cationic lipid is a lipid capable of being positively charged, e.g., under physiological conditions.
[0038] Exemplary cationic lipids include one or more amine group(s) which bear the positive charge. Examples of positively charged (cationic) lipids include, but are not limited to, N,N'-dimethyl-N,N'-dioctacyl ammonium bromide (DDAB) and chloride DDAC), N-(l-(2,3-dioleyloxy)propyl)-N,N,N-trimethylammonium chloride (DOTMA), 3|3-[N-(N',N'-dimethylaminoethyl)carbamoyl) cholesterol (DC-chol), l,2-dioleoyloxy-3-[trimethylammonio]-propane (DOTAP), l,2-dioctadecyloxy-3-[trimethylammonio]-propane (DSTAP), and 1,2-Attorney Docket No.: 62801.89W001dioleoyloxypropyl-3-dimethyl-hydroxy ethyl ammonium chloride (DORT), N,N-dioleyl-N,N-dimethylammonium chloride (DODAC), N,N-dimethyl-2,3-dioleyloxy)propylamine (DODMA), 1 ,2-Dioleoyl-3-Dimethylammonium-propane (DODAP), 1 ,2-Dioleoylcarbamyl-3- Dimethylammonium-propane (DOCDAP), 1 ,2-Dilineoyl-3-Dimethylammonium-propane (DLINDAP), 3-Dimethylamino-2-(Cholest-5-en-3-beta-oxybutan-4-oxy)-l-(cis,cis-9,12-octadecadienoxy)propane (CLinDMA), 2-[5'-(cholest-5-en-3-beta-oxy)-3'-oxapentoxy)-3-dimethyl-l-(cis, cis-9',12'-octadecadienoxy)propane (CpLin DMA), N,N-Dimethyl-3,4-dioleyloxybenzylamine (DMOBA), and the cationic lipids described in e.g. Martin et al., Current Pharmaceutical Design, pages 1-394, the entire contents of which are incorporated by reference herein for all purposes. In some embodiments, the lipid-based carrier (or lipid nanoformulation) comprises more than one cationic lipid.
[0039] In some embodiments, the lipid-based carrier (or lipid nanoformulation) comprises a cationic lipid having an effective pKa over 6.0. In some embodiments, the lipid-based carrier (or lipid nanoformulation) further comprises a second cationic lipid having a different effective pKa (e.g., greater than the first effective pKa) than the first cationic lipid.
[0040] In some embodiments, cationic lipids that can be used in the lipid-based carrier (or lipid nanoformulation) include, for example those described in Table 4 of WO 2019 / 217941, the entire contents of which are incorporated by reference herein for all purposes.
[0041] In some embodiments, the cationic lipid is an ionizable lipid (e.g., a lipid that is protonated at low pH, but that remains neutral at physiological pH). In some embodiments, the lipid-based carrier (or lipid nanoformulation) may comprise one or more additional ionizable lipids, different than the ionizable lipids described herein. Exemplary ionizable lipids include, but are not limited to,Attorney Docket No.: 62801.89W001(SM-102),(ALC-0315),(Lipid 10),(Lipid A9), and(DLin-MC3-DMA),
[0042] (see W02017004143A1, the entire contents of which is incorporated herein by reference for all purposes).
[0043] In some embodiments, the lipid-based carrier (or lipid nanoformulation) further comprises one or more compounds described by WO 2021 / 113777 (e.g., a lipid of Formula (3) such as a lipid of Table 3 of WO 2021 / 113777), the entire contents of which are incorporated by reference herein for all purposes.
[0044] In one embodiment, the ionizable lipid is a lipid disclosed in Hou, X., et al. Nat Rev Mater 6, 1078-1094 (2021). https: / / doi.org / 10.1038 / s41578-021-00358-0 (e.g., L319, C12-200, and DLin-MC3-DMA), (the entire contents of which are incorporated by reference herein for all purposes).
[0045] Examples of other ionizable lipids that can be used in lipid-based carrier (or lipid nanoformulation) include, without limitation, one or more of the following formulas: X of US 2016 / 0311759; I of US 20150376115 or in US 2016 / 0376224; Compound 5 or Compound 6 in US 2016 / 0376224; I, IA, or II of US 9,867,888; I, II or III of US 2016 / 0151284; I, IA, II, or HA of US 2017 / 0210967; I-c of US 2015 / 0140070; A of US 2013 / 0178541; I of US 2013 / 0303587 or US 2013 / 0123338; I of US 2015 / 0141678; II, III, IV, or V of US 2015 / 0239926; I of USAttorney Docket No.: 62801.89W0012017 / 0119904; T or II of WO 2017 / 117528; A of US 2012 / 0149894; A of US 2015 / 0057373; A of WO 2013 / 116126; A of US 2013 / 0090372; A of US 2013 / 0274523; A of US 2013 / 0274504; A of US 2013 / 0053572; A of WO 2013 / 016058; A of WO 2012 / 162210; I of US 2008 / 042973; I, II, III, or IV of US 2012 / 01287670; I or II of US 2014 / 0200257; I, II, or III of US 2015 / 0203446; I or III of US 2015 / 0005363; I, IA, IB, IC, ID, II, IIA, IIB, IIC, IID, or III-XXIV of US 2014 / 0308304; of US 2013 / 0338210; I, II. Ill, or IV of WO 2009 / 132131; A of US 2012 / 01011478; I or XXXV of US 2012 / 0027796; XIV or XVII of US 2012 / 0058144; of US 2013 / 0323269; I of US 2011 / 0117125; I, II. or III of US 2011 / 0256175; I, II, III, IV, V, VI, VII, VIII, IX, X, XI, XII of US 2012 / 0202871; I, II, III, IV, V, VI, VII, VIII, X, XII, XIII, XIV, XV, or XVI of US 2011 / 0076335; I or II of US 2006 / 008378; I of W02015 / 074085 (e.g., ATX-002); I of US 2013 / 0123338; I or X-A-Y-Z of US 2015 / 0064242; XVI, XVII. or XVIII of US 2013 / 0022649; I, II, or III of US 2013 / 0116307; I, II, or III of US 2013 / 0116307; I or II of US 2010 / 0062967; I-X of US 2013 / 0189351; I of US 2014 / 0039032; V of US 2018 / 0028664; I of US 2016 / 0317458; I of US 2013 / 0195920; 5, 6. or 10 of US 10,221,127: III-3 of WO 2018 / 081480; 1-5 or 1-8 ofWO 2020 / 081938; I of WO 2015 / 199952 (e.g., compound 6 or 22) and Table 2 therein; 18 or 25 of US 9,867,888; A of US 2019 / 0136231; II of WO 2020 / 219876; 1 of US 2012 / 0027803; OF-02 of US 2019 / 0240349; 23 of US 10,086,013; cKK-E12 / A6 of Miao et al (2020); C12-200 of WO 2010 / 053572; 7C1 of Dahlman et al (2017); 304-013 or 503-013 of Whitehead et al; TS-P4C2 of U S9, 708, 628; I of WO 2020 / 106946; I of WO 2020 / 106946; (1), (2), (3), or (4) of WO 2021 / 113777; and any one of Tables 1-16 of WO 2021 / 113777, the entire contents of each of which are incorporated by reference herein for all purposes.
[0046] In some embodiments, the lipid-based earner (or lipid nanoformulation) further includes biodegradable ionizable lipids, for instance, (9Z,12Z)-3-((4,4-bis(octyloxy)butanoyl)oxy)-2-((((3- (diethylamino)propoxy)carbonyl)oxy)methyl)propyl octadeca-9.12-dienoate, also called 3- ((4,4-bis(octyloxy)butanoyl)oxy)-2-((((3-(diethylamino)propoxy)carbonyl)oxy)methyl)propyl (9Z,12Z)-octadeca-9,12-dienoate). See, e.g., lipids of WO 2019 / 067992, WO 2017 / 173054, WO 2015 / 095340, and WO 2014 / 136086, the entire contents of each of which are incorporated by reference herein for all purposes.4.9.1.2 Non-Cationic Lipids (e.g., Phospholipids)
[0047] In some embodiments, the lipid-based carrier (or lipid nanoformulation) further comprises one or more non-cationic lipids. In some embodiments, the non-cationic lipid is aAttorney Docket No.: 62801.89W001phospholipid. In some embodiments, the non-cationic lipid is a phospholipid substitute or replacement. In some embodiments, the non-cationic lipid is a negatively charged (anionic) lipid.
[0048] Exemplary non-cationic lipids include, but are not limited to, distearoyl-sn-glycero-phosphoethanolamine, distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), dipalmitoylphosphatidylcholine (DPPC), dioleoylphosphatidylglycerol (DOPG), dipalmitoylphosphatidylglycerol (DPPG), dioleoyl-phosphatidylethanolamine (DOPE), palmitoyloleoylphosphatidylcholine (POPC), palmitoyloleoylphosphatidylethanolamine (POPE), dioleoyl-phosphatidylethanolamine 4-(N-maleimidomethyl)-cyclohexane- 1-carboxylate (DOPE-mal), dipalmitoyl phosphatidyl ethanolamine (DPPE), dimyristoylphosphoethanolamine (DMPE), distearoyl-phosphatidyl-ethanolamine (DSPE), monomethyl-phosphatidylethanolamine (such as 16-O-monomethyl PE), dimethyl- phosphatidylethanolamine (such as 16-O-dimethyl PE), 18-1-trans PE, l-stearoyl-2-oleoyl-phosphatidyethanolamine (SOPE), hydrogenated soy phosphatidylcholine (HSPC), egg phosphatidylcholine (EPC), dioleoylphosphatidylserine (DOPS), sphingomyelin (SM), dimyristoyl phosphatidylcholine (DMPC), dimyristoyl phosphatidylglycerol (DMPG), distearoylphosphatidylglycerol (DSPG), dierucoylphosphatidylcholine (DEPC), palmitoyloleyolphosphatidylglycerol (POPG), dielaidoylphosphatidylethanolamine (DEPE), 1,2-dilauroyl- sn-glycero-3-phosphocholine (DLPC), Sodium 1,2- ditetradecanoyl-sn-glycero-3-phosphate (DMPA), phosphatidylcholine (lecithin), phosphatidylethanolamine, lysolecithin, lysophosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, sphingomyelin, egg sphingomyelin (ESM), phosphatidylethanolamine (cephalin), cardiolipin, phosphatidic acid, cerebrosides, dicetylphosphate, lysophosphatidylcholine, dilinoleoylphosphatidylcholine, or mixtures thereof. It is understood that other diacylphosphatidylcholine and diacylphosphatidylethanolamine phospholipids can also be used. The acyl groups in these lipids are preferably acyl groups derived from fatty acids having C10-C24 carbon chains, e.g., lauroyl, myristoyl, paimitoyl, stearoyl, or oleoyl. Additional exemplary lipids, in certain embodiments, include, without limitation, those described in Kim et al. (2020) dx.doi.org / 10.1021 / acs.nanolett.0c01386, the entire contents of which are incorporated by reference herein for all purposes. Such lipids include, in some embodiments, plant lipids found to improve liver transfection with mRNA (e.g., DGTS).
[0049] In some embodiments, the lipid-based carrier (or lipid nanoformulation) may comprise a combination of distearoylphosphatidylcholine / cholesterol,Attorney Docket No.: 62801.89W001dipalmitoylphosphatidylcholine / cholesterol, dimyrystoylphosphatidylcholine / cholesterol, 1 ,2-Dioleoyl-sn-glycero-3-phosphocholine (DOPC)Zcholesterol, or egg sphingomyelin / cholesterol.
[0050] Other examples of suitable non-cationic lipids include, without limitation, nonphosphorous lipids such as, e.g., stearylamine, dodecylamine, hexadecylamine, acetyl palmitate, glycerol ricinoleate, hexadecyl stearate, isopropyl myristate, amphoteric acrylic polymers, triethanolamine-lauryl sulfate, alkyl-aryl sulfate polyethyloxylated fatty acid amides, dioctadecyl dimethyl ammonium bromide, ceramide, sphingomyelin, and the like. Other noncationic lipids are described in WO 2017 / 099823 or US 2018 / 0028664, the entire contents of each of which are incorporated by reference herein for all purposes.
[0051] In one embodiment, the lipid-based carrier (or lipid nanoformulation) further comprises one or more non-cationic lipid that is oleic acid or a compound of Formula I. II, or IV of US 2018 / 0028664, the entire contents of which are incorporated by reference herein for all purposes.
[0052] The non-cationic lipid content can be, for example, 0-30% (mol) of the total lipid components present. In some embodiments, the non-cationic lipid content is 5-20% (mol) or 10-15% (mol) of the total lipid components present.
[0053] In some embodiments, the lipid-based carrier (or lipid nanoformulation) further comprises a neutral lipid, and the molar ratio of an ionizable lipid to a neutral lipid ranges from about 2:1 to about 8:1 (e.g., about 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, or 8:1).
[0054] In some embodiments, the lipid-based earner (or lipid nanoformulation) does not include any phospholipids.
[0055] In some embodiments, the lipid-based carrier (or lipid nanoformulation) can further include one or more phospholipids, and optionally one or more additional molecules of similar molecular shape and dimensions having both a hydrophobic moiety and a hydrophilic moiety (e.g., cholesterol).4.9.1.3 Structural Lipids
[0056] The lipid-based carrier (or lipid nanoformulation) described herein may further comprise one or more structural lipids. As used herein, the term “structural lipid” refers to sterols (e.g., cholesterol) and also to lipids containing sterol moieties.
[0057] Incorporation of structural lipids in the lipid nanoparticle may help mitigate aggregation of other lipid in the particle. Structural lipids can be selected from the group including but not limited to, cholesterol or cholesterol derivative, fecosterol, sitosterol, ergosterol,Attorney Docket No.: 62801.89W001campesterol, stigmasterol, brassicasterol, tomatidine, tomatine, ursolic acid, alpha-tocopherol, hopanoids, phytosterols, steroids, and mixtures thereof. In some embodiments, the structural lipid is a sterol. In certain embodiments, the structural lipid is a steroid. In certain embodiments, the structural lipid is cholesterol. In certain embodiments, the structural lipid is an analog of cholesterol. In certain embodiments, the structural lipid is alpha-tocopherol.
[0058] In some embodiments, structural lipids may be incorporated into the lipid-based carrier at molar ratios ranging from about 0.1 to 1.0 (cholesterol phospholipid).
[0059] In some embodiments, sterols, when present, can include one or more of cholesterol or cholesterol derivatives, such as those described in WO 2009 / 127060 or US 2010 / 0130588, the entire contents of each of which are incorporated by reference herein for all purposes. Additional exemplary sterols include phytosterols, including those described in Eygeris et al. (2020), Nano Lett. 2020;20(6):4543-4549, the entire contents of which are incorporated by reference herein for all purposes.
[0060] In some embodiments, the structural lipid is a cholesterol derivative. Non-limiting examples of cholesterol derivatives include polar analogues such as 5a-cholestanol, 53-coprostanol, cholesteryl- (2’ -hydroxy )-ethyl ether, cholesteryl- (4'- hydroxy)-butyl ether, and 6-ketocholestanol; non-polar analogues such as 5a-cholestane, cholestenone, 5a-cholestanone, 5p-cholestanone, and cholesteryl decanoate; and mixtures thereof. In some embodiments, the cholesterol derivative is a polar analogue, e.g., cholesteryl-(4'-hydroxy)-butyl ether. Exemplary cholesterol derivatives are described in WO 2009 / 127060 and US 2010 / 0130588, the entire contents of each of which are incorporated by reference herein for all purposes.
[0061] In some embodiments, the lipid-based carrier (or lipid nanoformulation) further comprises sterol in an amount of 0-50 mol% (e.g., 0-10 mol %, 10-20 mol %, 20-50 mol%, 20-30 mol %, 30-40 mol %, or 40-50 mol %) of the total lipid components.4.9.1.4 Polymers and Polyethylene Glycol (PEG) - Lipids
[0062] In some embodiments, the lipid-based carrier (or lipid nanoformulation) may include one or more polymers or co-polymers, e.g., poly(lactic-co-glycolic acid) (PFAG) nanoparticles.
[0063] In some embodiments, the lipid-based carrier (or lipid nanoformulation) may include one or more polyethylene glycol (PEG) lipid. Examples of useful PEG-lipids include, but are not limited to, l,2-Diacyl-sn-Glycero-3- Phosphoethanolamine-N-[Methoxy(Polyethylene glycol)-350] (mPEG 350 PE); 1,2-Diacyl-sn- Glycero-3-Phosphoethanolamine-N-[Methoxy(PolyethyleneAttorney Docket No.: 62801.89W001glycol)-550] (mPEG 550 PE); 1,2- Diacyl-sn-Glycero-3-Phosphoethanolamine-N-[Methoxy(Polyethylene glycol)-750] (mPEG 750 PE); l,2-Diacyl-sn-Glycero-3-Phosphoethanolamine-N-[Methoxy(Polyethylene glycol)-1000] (mPEG 1000 PE); 1,2-Diacyl-sn-Glycero-3-Phosphoethanolamine-N-[Methoxy(Polyethylene glycol)-2000] (mPEG 2000 PE); 1,2-Diacyl-sn-Glycero-3-Phosphoethanolamine-N- [Methoxy(Polyethylene glycol)-3000] (mPEG 3000 PE); l,2-Diacyl-sn-Glycero-3- Phosphoethanolamine-N-[Methoxy(Polyethylene glycol)-5000] (mPEG 5000 PE); N-Acyl- Sphingosine- l-[Succinyl(Methoxy Polyethylene Glycol) 750] (mPEG 750 Ceramide); N-Acyl- Sphingosine- l-[Succinyl(Methoxy Polyethylene Glycol) 2000] (mPEG 2000 Ceramide); and N- Acyl-Sphingosine-l-[Succinyl(Methoxy Polyethylene Glycol) 5000] (mPEG 5000 Ceramide). In some embodiments, the PEG lipid is a polyethyleneglycoldiacylglycerol (i.e., polyethyleneglycol diacylglycerol (PEG-DAG), PEG-cholesterol, or PEG-DMB) conjugate.
[0064] In some embodiments, the lipid-based carrier (or nanoformulation) includes one or more conjugated lipids (such as PEG-conjugated lipids or lipids conjugated to polymers described in Table 5 of WO 2019 / 217941, the entire contents of which are incorporated by reference herein for all purposes). In some embodiments, the one or more conjugated lipids is formulated with one or more ionic lipids (e.g., non-cationic lipid such as a neutral or anionic, or zwitterionic lipid); and one or more sterols e.g., cholesterol).
[0065] The PEG conjugate can comprise a PEG-dilaurylglycerol (Cl 2), a PEG-dimyristylglycerol (C14), a PEG-dipalmitoylglycerol (C16), a PEG-disterylglycerol (C18), PEG-dilaurylglycamide (C12), PEG-dimyristylglycamide (C14), PEG-dipalmitoylglycamide (C16), and PEG-disterylglycamide (Cl 8).
[0066] In some embodiments, conjugated lipids, when present, can include one or more of PEG-diacylglycerol (DAG) (such as l-(monomethoxy-polyethyleneglycol)-2,3-dimyristoylglycerol (PEG-DMG)), PEG-dialkyloxypropyl (DAA), PEG-phospholipid, PEG-ceramide (Cer), a pegylated phosphatidylethanoloamine (PEG-PE), PEG succinate diacylglycerol (PEGS-DAG) (such as 4-0-(2',3'-di(tetradecanoyloxy)propyl-l-0-(w- methoxy(polyethoxy)ethyl) butanedioate (PEG-S-DMG)), PEG dialkoxypropylcarbam, N- (carbonyl-methoxypolyethylene glycol 2000)- 1 ,2-distearoyl-sn-glycero-3-phosphoethanolamine sodium salt, and those described in Table 2 of WO 2019 / 051289 (the entire contents of which are incorporated by reference herein for all purposes), and combinations of the foregoing.Attorney Docket No.: 62801.89W001
[0067] Additional exemplary PEG-lipid conjugates are described, for example, in US 5,885,613, US 6,287,591, US 2003 / 0077829, US 2003 / 0077829, US 2005 / 0175682, US 2008 / 0020058. US 2011 / 0117125, US 2010 / 0130588, US 2016 / 0376224, US 2017 / 0119904, US 2018 / 0028664, and WO 2017 / 099823, the entire contents of each of which are incorporated by reference herein for all purposes.
[0068] In some embodiments, the PEG-lipid is a compound of Formula III, III-a-I. III-a-2, III-b-1, III-b-2, or V of US 2018 / 0028664, which is incorporated herein by reference in its entirety. In some embodiments, the PEG-lipid is of Formula II of US 2015 / 0376115 or US 2016 / 0376224, the entire contents of each of which are incorporated by reference herein for all purposes. In some embodiments, the PEG-DAA conjugate can be, for example, PEG-dilauryloxypropyl, PEG-dimyristyloxypropyl, PEG-dipalmityloxypropyl, or PEG-distearyloxypropyl. In some embodiments, the PEG-lipid includes one of the following:
[0069] In some embodiments, lipids conjugated with a molecule other than a PEG can also be used in place of PEG-lipid. For example, polyoxazoline (POZ)-lipid conjugates, polyamide-lipid conjugates (such as ATTA-lipid conjugates), and cationic-polymer lipid (GPL) conjugates can be used in place of or in addition to the PEG-lipid.
[0070] Exemplary conjugated lipids, e.g., PEG-lipids, (POZ)-lipid conjugates. ATTA-lipid conjugates and cationic polymer-lipids, include those described in Table 2 of WO 2019 / 051289A9, the entire contents of which are incorporated by reference herein for all purposes.
[0071] In some embodiments, the conjugated lipid e.g., the PEGylated lipid) can be presentAttorney Docket No.: 62801.89W001in an amount of 0-20 mol% of the total lipid components present in the lipid-based carrier (or lipid nanoformulation). In some embodiments, the conjugated lipid (e.g., the PEGylated lipid) content is 0.5-10 mol% or 2-5 mol% of the total lipid components.
[0072] When needed, the lipid-based carrier (or lipid nanoformulation) described herein may be coated with a polymer layer to enhance stability in vivo (e.g., sterically stabilized LNPs).
[0073] Examples of suitable polymers include, but are not limited to, polyethylene glycol), which may form a hydrophilic surface layer that improves the circulation half-life of liposomes and enhances the amount of lipid nanoformulations (e.g., liposomes or LNPs) that reach therapeutic targets. See, e.g., Working et al. J Pharmacol Exp Ther, 289: 1128-1133 (1999); Gabizon et al., J Controlled Release 53: 275-279 (1998); Adlakha Hutcheon et al., Nat Biotechnol 17; 775-779 (1999); and Koning et al., Biochim Biophys Acta 1420: 153-167 (1999), the entire contents of each of which are incorporated by reference herein for all purposes.4.9.1.5 Percentages of Lipid Nanoformulation Components
[0074] In some embodiments, the lipid-based carrier (or lipid nanoformulation) comprises one of more agent described herein (e.g., promoter, a nucleic acid molecule described herein (e.g., a DNA molecule described herein, an RNA molecule described herein), protein (e.g., therapeutic protein), vector, carrier, vaccine composition, and / or pharmaceutical composition), optionally a non-cationic lipid (e.g., a phospholipid), a sterol, a neutral lipid, and optionally conjugated lipid (e.g., a PEGylated lipid) that inhibits aggregation of particles. In some embodiments, the lipid-based carrier (or lipid nanoformulation) further comprises an agent described herein (e.g., promoter, a nucleic acid molecule described herein (e.g., a DNA molecule described herein, an RNA molecule described herein), protein (e.g., therapeutic protein), vector, carrier, vaccine composition, and / or pharmaceutical composition). The amounts of these components can be varied independently and to achieve desired properties. For example, in some embodiments, the ionizable lipid including the lipid compounds described herein is present in an amount from about 20 mol% to about 100 mol% (e.g., 20-90 mol%, 20-80 mol%, 20-70 mol%, 25-100 mol%, 30-70 mol%, 30-60 mol%, 30-40 mol%, 40-50 mol%, or 50-90 mol%) of the total lipid components; a non-cationic lipid (e.g., phospholipid) is present in an amount from about 0 mol% to about 50 mol% (e.g., 0-40 mol%, 0-30 mol%, 5-50 mol%, 5-40 mol%, 5-30 mol%, or 5-10 mol%) of the total lipid components, a conjugated lipid (e.g., a PEGylated lipid) in an amount from about 0.5 mol% to about 20 mol% (e.g., 1-10 mol% or 5-10%) of the total lipid components, and a sterol in an amountAttorney Docket No.: 62801.89W001from about 0 mol % to about 60 mol% (e.g., 0-50 mol%, 10-60 mol%, 10-50 mol%, 15-60 mol%, 15-50 mol%, 20-50 mol%, 20-40 mol%) of the total lipid components, provided that the total mol% of the lipid component does not exceed 100%.
[0075] In some embodiments, the lipid-based carrier (or lipid nanoformulation) comprises about 25-100 mol% of the ionizable lipid including the lipid compounds described herein, about 0-50 mol% phospholipid, about 0-50 mol% sterol, and about 0-10 mol% PEGylated lipid.
[0076] In some embodiments, the lipid-based carrier comprises an agent described herein (e.g., promoter, a nucleic acid molecule described herein (e.g., a DNA molecule described herein, an RNA molecule described herein), protein (e.g., therapeutic protein), vector, carrier, vaccine composition, and / or pharmaceutical composition) that is formulated in a lipid nanoparticle, wherein the lipid nanoparticle comprises about 25-100 mol% of the ionizable lipid including the lipid compounds described herein, about 0-50 mol% phospholipid, about 0-50 mol% sterol, and about 0-10 mol% PEGylated lipid. In some embodiments, the encapsulation efficiency of the agent described herein (e.g., promoter, a nucleic acid molecule described herein (e.g., a DNA molecule described herein, an RNA molecule described herein), protein (e.g., therapeutic protein), vector, carrier, vaccine composition, and / or pharmaceutical composition) may be at least 70%.
[0077] In one embodiment, the lipid-based carrier (or lipid nanoformulation) comprises about 25-100 mol% of the ionizable lipid including the lipid compounds described herein; about 0-40 mol% phospholipid (e.g., DSPC). about 0-50 mol% sterol (e.g., cholesterol), and about 0-10 mol% PEGylated lipid.
[0078] In some embodiments, the lipid-based carrier comprises an agent described herein (e.g., promoter, a nucleic acid molecule described herein e.g., a DNA molecule described herein, an RNA molecule described herein), protein (e.g., therapeutic protein), vector, carrier, vaccine composition, and / or pharmaceutical composition) that is formulated in a lipid nanoparticle, wherein the lipid nanoparticle comprises about 25-100 mol% of the ionizable lipid including the lipid compounds described herein; about 0-40 mol% phospholipid (e.g., DSPC), about 0-50 mol% sterol (e.g., cholesterol), and about 0-10 mol% PEGylated lipid. In some embodiments, the encapsulation efficiency of the agent described herein (e.g., promoter, a nucleic acid molecule described herein (e.g., a DNA molecule described herein, an RNA molecule described herein), protein (e.g., therapeutic protein), vector, earner, vaccine composition, and / or pharmaceutical composition) may be at least 70%.Attorney Docket No.: 62801.89W001
[0079] In some embodiments, the lipid-based carrier (or lipid nanoformulation) comprises about 30-60 mol% (e.g., about 35-55 mol%, or about 40-50 mol%) of the ionizable lipid including the lipid compounds described herein, about 0-30 mol% (e.g., 5-25 mol%, or 10-20 mol%) phospholipid, about 15-50 mol% (e.g., 18.5-48.5 mol%, or 30-40 mol%) sterol, and about 0-10 mol% (e.g., 1-5 mol%, or 1.5-2.5 mol%) PEGylated lipid.
[0080] In some embodiments, the lipid-based carrier comprises an agent described herein (e.g., promoter, a nucleic acid molecule described herein (e.g., a DNA molecule described herein, an RNA molecule described herein), protein (e.g., therapeutic protein), vector, carrier, vaccine composition, and / or pharmaceutical composition) that is formulated in a lipid nanoparticle, wherein the lipid nanoparticle comprises about 30-60 mol% (e.g., about 35-55 mol%, or about 40-50 mol%) of the ionizable lipid including the lipid compounds described herein, about 0-30 mol% (e.g., 5-25 mol%, or 10-20 mol%) phospholipid, about 15-50 mol% (e.g., 18.5-48.5 mol%, or 30-40 mol%) sterol, and about 0-10 mol% (e.g., 1-5 mol%, or 1.5-2.5 mol%) PEGylated lipid. In some embodiments, the encapsulation efficiency of the agent described herein (e.g., promoter, a nucleic acid molecule described herein (e.g., a DNA molecule described herein, an RNA molecule described herein), protein (e.g., therapeutic protein), vector, carrier, vaccine composition, and / or pharmaceutical composition) may be at least 70%.
[0081] In some embodiments, molar ratios of ionizable lipid / sterol / phospholipid (or another structural lipid) / PEG-lipid / additional components is varied in the following ranges: ionizable lipid (25-100%); phospholipid (DSPC) (0-40%); sterol (0-50%); and PEG lipid (0-5%).
[0082] In some embodiments, the lipid-based carrier comprises an agent described herein (e.g., promoter, a nucleic acid molecule described herein (e.g., a DNA molecule described herein, an RNA molecule described herein), protein (e.g., therapeutic protein), vector, carrier, vaccine composition, and / or pharmaceutical composition) that is formulated in a lipid nanoparticle, wherein the lipid nanoparticle comprises molar ratios of ionizable lipid / sterol / phospholipid (or another structural lipid) / PEG-lipid / additional components in the following ranges: ionizable lipid (25-100%); phospholipid (DSPC) (0-40%); sterol (0-50%); and PEG lipid (0-5%). In some embodiments, the encapsulation efficiency of the agent described herein (e.g., promoter, a nucleic acid molecule described herein (e.g., a DNA molecule described herein, an RNA molecule described herein), protein (e.g., therapeutic protein), vector, carrier, vaccine composition, and / or pharmaceutical composition) may be at least 70%.Attorney Docket No.: 62801.89W001
[0083] In some embodiments, the lipid-based carrier (or lipid nanoformulation) comprises, by mol% or wt% of the total lipid components, 50-75% ionizable lipid (including the lipid compound as described herein), 20-40% sterol (e.g., cholesterol or derivative), 0 to 10% non-cationic-lipid, and 1-10% conjugated lipid (e.g., the PEGylated lipid).
[0084] In some embodiments, the lipid-based carrier comprises an agent described herein (e.g., promoter, a nucleic acid molecule described herein (e.g., a DNA molecule described herein, an RNA molecule described herein), protein (e.g., therapeutic protein), vector, carrier, vaccine composition, and / or pharmaceutical composition) that is formulated in a lipid nanoparticle, wherein the lipid nanoparticle comprises, by mol% or wt% of the total lipid components, 50-75% ionizable lipid (including the lipid compound as described herein), 20-40% sterol (e.g., cholesterol or derivative), 0 to 10% non-cationic-lipid. and 1-10% conjugated lipid (e.g., the PEGylated lipid). In some embodiments, the encapsulation efficiency of the agent described herein (e.g., promoter, a nucleic acid molecule described herein (e.g., a DNA molecule described herein, an RNA molecule described herein), protein (e.g., therapeutic protein), vector, carrier, vaccine composition, and / or pharmaceutical composition) may be at least 70%.
[0085] In some embodiments, the lipid-based carrier (or lipid nanoformulation) comprises (i) an agent described herein (e.g., promoter, a nucleic acid molecule described herein (e.g., a DNA molecule described herein, an RNA molecule described herein), protein (e.g., therapeutic protein), vector, carrier, vaccine composition, and / or pharmaceutical composition); (ii) a cationic lipid comprising from 50 mol% to 65 mol% of the total lipid present in the lipid-based carrier; (iii) a non-cationic lipid comprising a mixture of a phospholipid and a cholesterol derivative thereof, wherein the phospholipid comprises from 3 mol% to 15 mol% of the total lipid present in the lipid-based carrier and the cholesterol or derivative thereof comprises from 30 mol% to 40 mol% of the total lipid present in the lipid-based carrier; and (iv) a conjugated lipid comprising 0.5 mol% to 2 mol% of the total lipid present in the particle.
[0086] In some embodiments, the lipid-based carrier (or lipid nanoformulation) comprises (i) an agent described herein (e.g., promoter, a nucleic acid molecule described herein (e.g., a DNA molecule described herein, an RNA molecule described herein), protein (e.g., therapeutic protein), vector, carrier, vaccine composition, and / or pharmaceutical composition); (ii) a cationic lipid comprising from 50 mol % to 85 mol % of the total lipid present in the lipid-based earner; (iii) a non-cationic lipid comprising from 13 mol % to 49.5 mol % of the total lipid present in the lipid-Attorney Docket No.: 62801.89W001based carrier; and (d) a conjugated lipid comprising from 0.5 mol % to 2 mol % of the total lipid present in the lipid-based carrier.
[0087] In some embodiments, the phospholipid component in the mixture may be present from 2 mol% to 20 mol%, from 2 mol% to 15 mol%, from 2 mol% to 12 mol%, from 4 mol% to 15 mol%, from 4 mol% to 10 mol%, from 5 mol% to 10 mol%, (or any fraction of these ranges) of the total lipid components. In some embodiments, the lipid-based carrier (or lipid nanoformulation) is phospholipid-free.
[0088] In some embodiments, the sterol component (e.g. cholesterol or derivative) in the mixture may comprise from 25 mol% to 45 mol%, from 25 mol% to 40 mol%, from 25 mol% to 35 mol%, from 25 mol% to 30 mol%, from 30 mol% to 45 mol%, from 30 mol% to 40 mol%, from 30 mol% to 35 mol%, from 35 mol% to 40 mol%. from 27 mol% to 37 mol%, or from 27 mol% to 35 mol% (or any fraction of these ranges) of the total lipid components.
[0089] In some embodiments, the non-ionizable lipid components in the lipid-based carrier (or lipid nanoformulation) may be present from 5 mol% to 90 mol%. from 10 mol% to 85 mol%, or from 20 mol% to 80 mol% (or any fraction of these ranges) of the total lipid components.
[0090] The ratio of total lipid components to the agent described herein (e.g., promoter, a nucleic acid molecule described herein (e.g., a DNA molecule described herein, an RNA molecule described herein), protein (e.g., therapeutic protein), vector, carrier, vaccine composition, and / or pharmaceutical composition) can be varied as desired. For example, the total lipid components to the agent described herein e.g., promoter, a nucleic acid molecule described herein (e.g., a DNA molecule described herein, an RNA molecule described herein), protein (e.g., therapeutic protein), vector, carrier, vaccine composition, and / or pharmaceutical composition) (mass or weight) ratio can be from about 10:1 to about 30:1. In some embodiments, the total lipid components to the agent described herein (e.g., promoter, a nucleic acid molecule described herein (e.g., a DNA molecule described herein, an RNA molecule described herein), protein (e.g., therapeutic protein), vector, carrier, vaccine composition, and / or pharmaceutical composition) ratio (mass / mass ratio; w / w ratio) can be in the range of from about 1:1 to about 25:1, from about 10:1 to about 14:1, from about 3:1 to about 15:1, from about 4:1 to about 10:1, from about 5:1 to about 9:1, or about 6:1 to about 9:1. The amounts of total lipid components and the agent described herein (e.g., promoter, a nucleic acid molecule described herein (e.g., a DNA molecule described herein, an RNA molecule described herein), protein (e.g., therapeutic protein), vector, carrier, vaccineAttorney Docket No.: 62801.89W001composition, and / or pharmaceutical composition) can be adjusted to provide a desired N / P ratio, for example, N / P ratio of 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, or higher. Generally, the lipid-based carrier (or lipid nanoformulation’s) overall lipid content can range from about 5 mg / ml to about 30 mg / mL. Nitrogemphosphate ratios (N:P ratio) is evaluated at values between 0.1 and 100.
[0091] The efficiency of encapsulation of an agent described herein (e.g., promoter, a nucleic acid molecule described herein (e.g., a DNA molecule described herein, an RNA molecule described herein), protein (e.g., therapeutic protein), vector, carrier, vaccine composition, and / or pharmaceutical composition) described herein that is encapsulated or otherwise associated with a lipid nanoformulation (e.g., liposome or LNP) after preparation, relative to the initial amount provided. The encapsulation efficiency is desirably high (e.g., at least 70%. 80%. 90%. 95%, close to 100%). The encapsulation efficiency may be measured, for example, by comparing the amount of the agent described herein (e.g., promoter, a nucleic acid molecule described herein (e.g., a DNA molecule described herein, an RNA molecule described herein), protein (e.g., therapeutic protein), vector, carrier, vaccine composition, and / or pharmaceutical composition) in a solution containing the liposome or LNP before and after breaking up the liposome or LNP with one or more organic solvents or detergents. An anion exchange resin may be used to measure the amount of free the agent described herein (e.g., promoter, a nucleic acid molecule described herein (e.g., a DNA molecule described herein, an RNA molecule described herein), protein (e.g., therapeutic protein), vector, carrier, vaccine composition, and / or pharmaceutical composition) in a solution. Fluorescence may be used to measure the amount of free the agent described herein (e.g., promoter, a nucleic acid molecule described herein (e.g., a DNA molecule described herein, an RNA molecule described herein), protein (e.g., therapeutic protein), vector, carrier, vaccine composition, and / or pharmaceutical composition) in a solution. For the lipid-based carrier (or lipid nanoformulation) described herein, the encapsulation efficiency of a protein and / or nucleic acid may be at least 50%, for example 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%. In some embodiments, the encapsulation efficiency may be at least 70%. In some embodiments, the encapsulation efficiency may be at least 80%. In some embodiments, the encapsulation efficiency may be at least 90%. In some embodiments, the encapsulation efficiency may be at least 95%.4.10 CellsAttorney Docket No.: 62801.89W001
[0092] Provided herein is a cell (e.g., a host cell) or a population of cells (e.g., a population of host cells) comprising one or more promoter described herein, a nucleic acid molecule described herein (e.g., a DNA molecule described herein)), a protein (e.g., therapeutic protein) made by a method described herein, a vector described herein, a carrier described herein, a vaccine composition described herein, and / or a pharmaceutical composition described herein. In some embodiments, the cell (or population of cells) is in vitro. In some embodiments, the cell (or population of cells) is in vivo. In some embodiments, the cell (or population of cells) is ex vivo.4.11 Vaccine Compositions
[0093] In some embodiments, one or more promoter described herein, a nucleic acid molecule described herein (e.g., a DNA molecule described herein), a protein (e.g., therapeutic protein) made by a method described herein, a vector described herein, a carrier described herein, a vaccine composition described herein, and / or a pharmaceutical composition described herein forms the basis for a vaccine composition. Therefore, provided herein are, inter alia, vaccine compositions (e.g., prime vaccine compositions, vaccine booster compositions, vaccine prime and booster compositions) comprising one or more promoter described herein, a nucleic acid molecule described herein (e.g., a DNA molecule described herein), a protein (e.g., therapeutic protein) made by a method described herein, a vector described herein, a carrier described herein, a vaccine composition described herein, and / or a pharmaceutical composition described herein.
[0094] In some embodiments, the vaccine composition is a prime vaccine composition of a prime-boost vaccine regimen. In some embodiments, the vaccine composition is a vaccine booster composition of a prime-boost vaccine regimen. In some embodiments, the vaccine composition is a vaccine prime and booster composition of a prime-boost vaccine regimen. In some embodiments, the vaccine composition can be utilized as a prime and / or a booster (e.g., as described herein). In some embodiments, the vaccine composition forms a single dose vaccine that does not require a booster.4.12 Pharmaceutical Compositions
[0095] Provided herein are, inter alia, pharmaceutical compositions comprising one or more promoter described herein, a nucleic acid molecule described herein (e.g., a DNA molecule described herein), a protein (e.g., therapeutic protein) made by a method described herein, a vectorAttorney Docket No.: 62801.89W001described herein, a carrier described herein, and / or a vaccine composition described herein; and a pharmaceutically acceptable excipient see, e.g., Remington’s Pharmaceutical Sciences (1990) Mack Publishing Co., Easton, PA, the entire contents of which is incorporated by reference herein for all purposes).
[0096] In one aspect, also provided herein are methods of making pharmaceutical compositions described herein comprising providing one or more promoter described herein, a nucleic acid molecule described herein e.g., a DNA molecule described herein), a protein {e.g., therapeutic protein) made by a method described herein, a vector described herein, a carrier described herein, and / or a vaccine composition described herein; and formulating it into a pharmaceutically acceptable composition by the addition of one or more pharmaceutically acceptable excipient.
[0097] Acceptable excipients {e.g., carriers and stabilizers) are preferably nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, or other organic acids; antioxidants including ascorbic acid or methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol;or m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, or other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose or sorbitol; salt-forming counter-ions such as sodium; metal complexes {e.g., Zn-protein complexes); and / or non-ionic surfactants such as TWEEN™, PLURONICS™ or polyethylene glycol (PEG).
[0098] A pharmaceutical composition may be formulated for any route of administration to a subject. The skilled person knows the various possibilities to administer a pharmaceutical composition described herein a in order to induce an immune response to the immunogens(s) and / or antigen(s) in the pharmaceutical composition. Non-limiting embodiments include parenteral administration, such as intramuscular, intradermal, subcutaneous, transcutaneous, or mucosal administration, e.g., inhalation, intranasal, oral, and the like. In one embodiment, the pharmaceutical composition is formulated for administration by intramuscular, intradermal, orAttorney Docket No.: 62801.89W001subcutaneous injection. Tn one embodiment, the pharmaceutical composition is formulated for administration by intramuscular injection. In one embodiment, the pharmaceutical composition is formulated for administration by intradermal injection. In one embodiment, the pharmaceutical composition is formulated for administration by subcutaneous injection. Injectables can be prepared in conventional forms, either as liquid solutions or suspensions. The injectables can contain one or more excipients. Exemplary excipients include, for example, water, saline, dextrose, glycerol or ethanol. In addition, if desired, the pharmaceutical compositions to be administered can also contain minor amounts of non-toxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents, stabilizers, solubility enhancers, or other such agents, such as for example, sodium acetate, sorbitan monolaurate, triethanolamine oleate or cyclodextrins. In some embodiments, the pharmaceutical composition is formulated in a single dose. In some embodiments, the pharmaceutical compositions if formulated as a multi-dose.
[0099] Pharmaceutically acceptable excipients used in the parenteral preparations described herein include for example, aqueous vehicles, nonaqueous vehicles, antimicrobial agents, isotonic agents, buffers, antioxidants, local anesthetics, suspending and dispersing agents, emulsifying agents, sequestering or chelating agents or other pharmaceutically acceptable substances. Examples of aqueous vehicles, which can be incorporated in one or more of the formulations described herein, include sodium chloride injection, Ringer’s injection, isotonic dextrose injection, sterile water injection, dextrose or lactated Ringer’s injection. Nonaqueous parenteral vehicles, which can be incorporated in one or more of the formulations described herein, include fixed oils of vegetable origin, cottonseed oil, com oil, sesame oil or peanut oil. Antimicrobial agents in bacteriostatic or fungistatic concentrations can be added to the parenteral preparations described herein and packaged in multiple-dose containers, which include phenols or cresols, mercurials, benzyl alcohol, chlorobutanol, methyl and propyl p-hydroxybenzoic acid esters, thimerosal, benzalkonium chloride or benzethonium chloride. Isotonic agents, which can be incorporated in one or more of the formulations described herein, include sodium chloride or dextrose. Buffers, which can be incorporated in one or more of the formulations described herein, include phosphate or citrate. Antioxidants, which can be incorporated in one or more of the formulations described herein, include sodium bisulfate. Local anesthetics, which can be incorporated in one or more of the formulations described herein, include procaine hydrochloride. Suspending and dispersing agents, which can be incorporated in one or more of the formulations described herein, includeAttorney Docket No.: 62801.89W001sodium carboxymethylcelluose, hydroxypropyl methylcellulose or polyvinylpyrrolidone. Emulsifying agents, which can be incorporated in one or more of the formulations described herein, include Polysorbate 80 (TWEEN® 80). A sequestering or chelating agent of metal ions, which can be incorporated in one or more of the formulations described herein, is EDTA. Pharmaceutical carriers, which can be incorporated in one or more of the formulations described herein, also include ethyl alcohol, polyethylene glycol or propylene glycol for water miscible vehicles; orsodium hydroxide, hydrochloric acid, citric acid or lactic acid for pH adjustment.
[0100] The precise dose to be employed in a pharmaceutical composition will also depend on the route of administration, and the seriousness of the condition caused by it, and should be decided according to the judgment of the practitioner and each subject’s circumstances. For example, effective doses may also vary depending upon means of administration, target site, physiological state of the subject (including age, body weight, and health), other medications administered, or whether therapy is prophylactic or therapeutic. Therapeutic dosages are preferably titrated to optimize safety and efficacy.4.13 Kits
[0101] Provided herein are kits comprising one or more promoter described herein, a nucleic acid molecule described herein (e.g., a DNA molecule described herein), a protein (e.g., therapeutic protein) made by a method described herein, a vector described herein, a carrier described herein, a vaccine composition described herein, and / or a pharmaceutical composition described herein. In addition, the kit may comprise a liquid vehicle for solubilizing or diluting any one of the foregoing, and / or technical instructions. The technical instructions of the kit may contain information about administration and dosage and subjects (e.g., subject groups).
[0102] In some embodiments, the promoter, the nucleic acid molecule (e.g., the DNA molecule)), the therapeutic protein, the vector, the carrier, the vaccine composition, and / or the pharmaceutical composition is provided in a separate part of the kit, wherein the promoter, the nucleic acid molecule (e.g., the DNA molecule)), the therapeutic protein, the vector, the carrier, the vaccine composition, and / or the pharmaceutical composition is optionally lyophilized, spray-dried, or spray-freeze dried. The kit may further contain as a part a vehicle (e.g., buffer solution) for solubilizing the dried or lyophilized pharmaceutical composition.
[0103] In some embodiments, the kit comprises a single dose container of the promoter, theAttorney Docket No.: 62801.89W001nucleic acid molecule (e.g., the DNA molecule)), the therapeutic protein, the vector, the carrier, the vaccine composition, and / or the pharmaceutical composition. In some embodiments, the kit comprises a multi-dose container for administration of the promoter, the nucleic acid molecule (e.g., the DNA molecule)), the therapeutic protein, the vector, the carrier, the vaccine composition, and / or the pharmaceutical composition and / or an administration device (e.g., an injector for intradermal injection or a syringe for intramuscular injection).
[0104] In some embodiments, the kit comprises an adjuvant in a separate container from the promoter, the nucleic acid molecule (e.g., the DNA molecule)), the therapeutic protein, the vector, the carrier, the vaccine composition, and / or the pharmaceutical composition. The kit may further contain technical instructions for mixing the promoter, the nucleic acid molecule (e.g., the DNA molecule)), the therapeutic protein, the vector, the carrier, the vaccine composition, and / or the pharmaceutical composition and the adjuvant prior to administration or for co-administration.
[0105] Any of the kits described herein may be used in any of the methods described herein, e.g., in § 4.14. Any of the kits described herein may be used in a treatment or prophylaxis as defined herein (e.g., for the treatment, amelioration, and / or prophylaxis of a disease).4.14 Methods of Use
[0106] Provided herein are various methods of utilizing the promoters described herein, nucleic acid molecules comprising the same (e.g., nucleic acid molecules described herein (e.g., DNA molecules described herein)), vectors described herein, carriers described herein, vaccine compositions described herein, and pharmaceutical compositions described herein.
[0107] Several of the methods described herein involve a subject. Exemplary subjects include mammals, e.g., humans, non-human mammals, e.g., non-human primates. In specific preferred embodiments, the subject is a human.4.14.1 Delivery
[0108] In one aspect, provided herein are methods of delivering a promoter described herein, a DNA molecule described herein, a vector described herein, or a carrier described herein to a cell, the method comprising delivering to the cell the promoter, the DNA molecule, the vector, the carrier, the vaccine composition, or the pharmaceutical composition, to thereby deliver the promoter, the DNA molecule, the vector, or the carrier to the cell.Attorney Docket No.: 62801.89W001
[0109] In some embodiments, the method is in vitro. In some embodiments, the cell is in vitro or ex vivo. In some embodiments, the cell is in a subject.
[0110] In one aspect, provided herein are in vitro methods of delivering a promoter described herein, a DNA molecule described herein, a vector described herein, or a carrier described herein to a cell in vitro, the method comprising delivering to the cell the promoter, the DNA molecule, the vector, the carrier, the vaccine composition, or the pharmaceutical composition, to thereby deliver the promoter, the DNA molecule, the vector, or the carrier to the cell in vitro.4.14.2 Protein Expression & Manufacturing
[0111] In one aspect, provided herein are in vitro methods of making a protein (e.g., a therapeutic protein (e.g., a therapeutic protein described herein)), the method comprising (a) culturing a population of cells in vitro (b) a DNA molecule described herein, a vector described herein, or a carrier described herein, to the population of cells; and (c) culturing the population of cells under conditions and for a period of time sufficient to allow for expression of the protein (e.g., therapeutic protein (e.g., a therapeutic protein described herein)); and (c) optionally isolating and / or purifying the expressed protein e.g., therapeutic protein (e.g., a therapeutic protein described herein)).
[0112] In some embodiments, the therapeutic protein is one described herein (or a variant thereof), see, e.g., § 4.6.1. In some embodiments, the therapeutic protein is described in § 4.6.1.
[0113] In one aspect, provided herein are methods of expressing a protein (e.g., a therapeutic protein) in a subject in need thereof, the method comprising administering to the subject a DNA molecule described herein, a vector described herein, a carrier described herein, a cell or population of cells described herein, a vaccine composition described herein, or a pharmaceutical composition described herein, to thereby express the protein (e.g., therapeutic protein) in the subject in need thereof. In some embodiments, the DNA molecule, vector, carrier, cell or population of cells, vaccine composition, or pharmaceutical composition is administered to the subject in an amount and for a time sufficient to express the protein in the subject.
[0114] In some embodiments, the therapeutic protein is one described herein (or a variant thereof), see, e.g., § 4.6.1. In some embodiments, the therapeutic protein is described in § 4.6.1.
[0115] In one aspect, provided herein are methods of expressing a protein (e.g., a therapeutic protein) in a subject in need thereof, the method comprising administering to the subject a proteinAttorney Docket No.: 62801.89W001(e.g., therapeutic protein) (or a pharmaceutical composition comprising the same) made by a method described herein (e.g., a method described in § 4.14.2), to thereby express the protein (e.g., therapeutic protein) in the subject in need thereof. In some embodiments, the protein (e.g., therapeutic protein) (or a pharmaceutical composition comprising the same) is administered to the subject in an amount and for a time sufficient to express the protein in the subject.
[0116] In some embodiments, the therapeutic protein is one described herein (or a variant thereof), see, e.g., § 4.6.1. In some embodiments, the therapeutic protein is described in § 4.6.1.
[0117] In one aspect, provided herein are methods of expressing a protein (e.g., a therapeutic protein) in a cell, the method comprising delivering to the cell a DNA molecule described herein, a vector described herein, a carrier described herein, a cell or population of cells described herein, a vaccine composition described herein, or a pharmaceutical composition described herein, to thereby express the protein (e.g., therapeutic protein) in the cell. In some embodiments, the DNA molecule, vector, carrier, cell or population of cells, vaccine composition, or pharmaceutical composition is delivered to the cell in an amount and for a time sufficient to express the protein in the cell.
[0118] In some embodiments, the therapeutic protein is one described herein (or a variant thereof), see, e.g., § 4.6.1. In some embodiments, the therapeutic protein is described in § 4.6.1.
[0119] In some embodiments, the method is in vitro. In some embodiments, the cell is in vitro or ex vivo. In some embodiments, the cell is in a subject.
[0120] In one aspect, provided herein are methods of expressing a protein (e.g., a therapeutic protein) in a cell, the method comprising delivering to the cell a protein (e.g., therapeutic protein) (or a pharmaceutical composition comprising the same) made by a method described herein (e.g., a method described in § 4.14.2), to thereby express the protein (e.g., therapeutic protein) in the cell. In some embodiments, the protein (e.g., therapeutic protein) (or a pharmaceutical composition comprising the same) is delivered to the cell in an amount and for a time sufficient to express the protein in the cell.
[0121] In some embodiments, the therapeutic protein is one described herein (or a variant thereof), see, e.g., § 4.6.1. In some embodiments, the therapeutic protein is described in § 4.6.1.
[0122] In some embodiments, the method is in vitro. In some embodiments, the cell is in vitro or ex vivo. In some embodiments, the cell is in a subject.4.14.3 Treatment, Amelioration, and Prevention of DiseasesAttorney Docket No.: 62801.89W001
[0123] In one aspect, provided herein are methods of treating, ameliorating, or preventing a disease in a subject in need thereof, the method comprising administering to the subject a DNA molecule described herein, a vector described herein, a carrier described herein, a cell or population of cells described herein, a vaccine composition described herein, or a pharmaceutical composition described herein, to thereby treat, ameliorate, or prevent the disease in the subject. In some embodiments, the DNA molecule, vector, earner, cell or population of cells, vaccine composition, or pharmaceutical composition is administered to the subject in an amount and for a time sufficient to treat, ameliorate, or prevent the disease in the subject.
[0124] In one aspect, provided herein are methods of treating, ameliorating, or preventing a disease in a subject in need thereof, the method comprising administering to the subject a protein (e.g., therapeutic protein) (or a pharmaceutical composition comprising the same) made by a method described herein (e.g., a method described in § 4.14.2), to thereby treat the disease in the subject. In some embodiments, the protein or pharmaceutical composition is administered to the subject in an amount and for a time sufficient to treat, ameliorate, or prevent the disease in the subject.
[0125] In one aspect, provided herein is a use of a DNA molecule described herein, a vector described herein, a carrier described herein, a cell or population of cells described herein, a vaccine composition described herein, or a pharmaceutical composition described herein for the manufacture of a medicament.
[0126] In one aspect, provided herein is a use of a DNA molecule described herein, a vector described herein, a carrier described herein, a cell or population of cells described herein, a vaccine composition described herein, or a pharmaceutical composition described herein for the manufacture of a medicament for the treatment, amelioration, or prevention of a disease in a subject.
[0127] In a further aspect, provided herein is a DNA molecule described herein, a vector described herein, a carrier described herein, a cell or population of cells described herein, a vaccine composition described herein, or a pharmaceutical composition described herein for use in therapy. In a further aspect, provided herein is a DNA molecule described herein, a vector described herein, a carrier described herein, a cell or population of cells described herein, a vaccine composition described herein, or a pharmaceutical composition described herein for use in a method of treating, ameliorating, or preventing a disease in a subject in need thereof, the method comprisingAttorney Docket No.: 62801.89W001administering to the subject the DNA molecule, the vector, the carrier, the cell or population of cells, the vaccine composition, or the pharmaceutical composition described herein.
[0128] In one aspect, provided herein is a use of a protein (e.g., therapeutic protein) (or a pharmaceutical composition comprising the same) made by a method described herein (e.g., a method described in § 4.14.2) for the manufacture of a medicament.
[0129] In one aspect, provided herein is a use of a protein (e.g., therapeutic protein) (or a pharmaceutical composition comprising the same) made by a method described herein (e.g., a method described in § 4.14.2) for the manufacture of a medicament for the treatment, amelioration, or prevention of a disease in a subject.
[0130] In a further aspect, provided herein is a protein (e.g., therapeutic protein) (or a pharmaceutical composition comprising the same) made by a method described herein e.g., a method described in § 4.14.2) for use in therapy. In a further aspect, provided herein is a protein (e.g., therapeutic protein) (or a pharmaceutical composition comprising the same) made by a method described herein (e.g., a method described in § 4.14.2) for use in a method of treating, ameliorating, or preventing a disease in a subject in need thereof, the method comprising administering to the subject protein (e.g., therapeutic protein) (or the pharmaceutical composition comprising the same) described herein.
[0131] In some embodiments, the disease is a proinflammatory disease, an autoimmune disease, an infection, a cancer, a neurological condition, an eye condition, a dermatological condition, transplant rejection, a blood disorder, a cardiovascular disease, a metabolic disease, bone disease, an endocrine disease, a genetic disease, a lipid disease, a uric acid disease, a calcium disease, or a drug toxicity.
[0132] Exemplary pro-inflammatory diseases include, but are not limited to, arthritis, rheumatoid arthritis, psoriasis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, multiple sclerosis, pericarditis, cryopyrin-associated periodic syndromes, systemic lupus erythematosus, chronic granulomatous disease, gout, systemic juvenile idiopathic arthritis, transplant rejection, diabetes, asthma, and eosinophilic asthma.
[0133] Exemplary autoimmune diseases include, but are not limited to, multiple sclerosis, Crohn’s disease, ulcerative colitis, systemic lupus erythematosus, diabetes, rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, arthritis, autoimmune pericarditis, Cryopyrin-associated autoinflammatory syndromes (CAPS), and autoimmune diabetes mellitus.Attorney Docket No.: 62801.89W001
[0134] Cancers include, e.g., solid tumors and liquid cancers. Exemplary cancers include, but are not limited to, colon cancer, rectal cancer, colorectal cancer, skin cancer (e.g., melanoma), lung cancer, breast cancer, gastric cancer, leukemia, and lymphoma. Exemplary metabolic diseases include, but are not limited to, mucopolysaccharidosis.
[0135] Exemplary cardiovascular diseases include, but are not limited to, myocardial ischemia, myocardial infarction, and hypercholesterolemia. Exemplary bone diseases include, but are not limited to, hypophosphatasia. Exemplary endocrine diseases include, but are not limited to. diabetes. Exemplary neurological diseases include, but are not limited to, Fabry disease. Exemplary genetic disease include, but are not limited, to, Pompe disease, mucopolysaccharidosis VI, lysosomal acid lipase deficiency, atypical hemolytic uremic syndrome, cystic fibrosis, and Fabry disease. Exemplary lipid diseases include, but are not limited to. lipodystrophy, and cystic fibrosis, Exemplary uric acid diseases include, but are not limited to, hyperuricemia. Exemplary calcium diseases include, but are not limited to, hypocalcemia. Exemplary infections include, but are not limited to, viral infections, bacterial infections, parasite infections, yeast infections, and fungal infections. Exemplary blood disorders include, but are not limited to, neutropenia, anemia, paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and thrombocytopenia. Exemplary drug toxicities include, but are not limited to, methotrexate toxicity and dabigatran toxicity.5. EXAMPLESTABLE OF CONTENTS5.1. Example 1. Design of Promoter Sequences & Generation of DNA Encoding Target Protein & Comprising Promoter Sequence.5.2 Example 2. Effect of Promoters on Protein Expression in Multiple Cell Lines.5.1 Example 1. Design of Promoter Sequences & Generation of DNA Encoding Target Protein & Comprising Promoter Sequence.
[0136] The individual promoters set forth in Table 2 above, respectively, were designed by the inventors through a process involving, e.g., rational design and experimental functional screening. Each of the promoters was made using standard polynucleotide synthesis methods known in the art. To assess the activity of the promoter sequences, the promoter sequences were combined with a DNA polynucleotide encoding a reporter protein (eGFP) as described below.Attorney Docket No.: 62801.89W0015.1.1 Design of Pooled Oligonucleotide Library
[0137] First, the promoter sequences were tested within a screening library containing 9642 other promoter sequences (10042 sequences total). Of these additional sequences, 9468 were derived from the human genome, 152 were derived from viral genomes, and 24 were curated from the literature (a mix of synthetic and viral promoters). If necessary, sequences were edited to remove recognition sites for restriction enzymes (RE) used in the library construction process. All sequences were a maximum of 160bp.
[0138] This set of 10042 sequences was used to construct an oligonucleotide pool. Each sequence in the oligonucleotide pool was 230bp and contained the promoter, DNA sequences for library construction, and a unique barcode for each promoter.
[0139] The unique 12bp barcodes were designed such that each barcode sequence had a minimum of 3bp differences from all other barcodes. Each promoter sequence element was linked to three randomized barcodes, such that the total pooled oligonucleotide library contained 30126 (10042 * 3) unique sequences.5.1.2 Plasmid Library Construction
[0140] The promoter oligonucleotide pools were cloned into a digested plasmid vector by Gibson assembly replacing the promoter, and transgenes from the vector. The assembled product was then transformed into bacteria and amplified to generate an intermediate library. Colony PCR and Sanger sequencing was performed to verify correct insertion of the oligo library. Isolated plasmid was amplified by Illumina compatible primer sequences and sequenced by Illumina sequencing to assess the complexity and quality of the library. Additional elements of the expression cassette were cloned in this library to produce the final library.
[0141] Circular dsDNA (cdsDNA) was prepared from the plasmid library. Briefly, utilizing the plasmid library as template, the PCR the region encompassing the expression cassette was amplified. DNA was digested with a specific restriction enzyme to generate complementary 5’ and 3’ overhangs and the DNA was circularized using DNA ligase. Residual linear DNA was removed by incubation with T5 exonuclease.
[0142] The region in the cdsDNA containing the barcodes was amplified by PCR and the product was sequenced by high throughput sequencing (NGS) to confirm the coverage of the elements in the library.Attorney Docket No.: 62801.89W0015.2 Example 2. Effect of Promoters on Protein Expression in Multiple Cell Lines.
[0143] The following Example shows the level of protein (eGFP) expressed by nucleic acid molecules comprising a select promoters in two different hepatocyte cell lines (Hela cells and AML 12 cells) in vitro.5.2.1 Cellular Assays
[0144] Briefly, the cdsDNA library was transfected in 2 different cell lines - AML12 and HeLa. The cells were plated at 250,000 cells / well of a 6-well plate. The cells were transfected with Ipg of the cdsDNA library / well with the mirusBio mRNA transfection reagent and assessed for GFP expression via Flow cytometry and microscopy on Day 1 and Day2 post transfection. Two wells each of AML 12 and HUH7 cells were harvested for sequencing at 48h.5.2.2 Sequencing & Data Analysis
[0145] We used next-generation sequencing (NGS) to evaluate the expression of each sequence element in our library.
[0146] To evaluate the activity of each promoter element. NGS was used to quantify the representation of each barcode (and thus each promoter element) in the transcribed RNA generated within transfected cells A region encompassing the barcodes in both cDNA (produced by reversetranscription of the library-derived RNA) and DNA samples was amplified by PCR. Assembled Illumina libraries were sequenced.
[0147] From the sequencing reads for each library the number of reads that can be unambiguously mapped back to each known barcode sequence were counted. After mapping, the raw data for analysis were thus (1) the read count for each barcode in the input DNA, and (2) the read count for each barcode in the RNA library for each replicate for each cell type.
[0148] Promoter sequences were first filtered that had low representation in the input DNA library: a promoter was required to have at least 2 barcodes with at least 3 reads-per-million to be considered for analysis. After filtering, 8154 of our initial 100042 promoter sequences were retained.
[0149] Subsequently, the DNA read counts and RNA read counts were used to estimate an expression score for each promoter. Within each cell type, RNA barcode counts across replicates and barcodes were statistically aggregated to generate an RNA count for each promoter. The RNAAttorney Docket No.: 62801.89W001count was then normalized by dividing it by the aggregated DNA count for that promoter, and the base-2 logarithm of this ration taken. The final expression score was thus the log2 fold-change of the RNA counts for each promoter relative to the DNA counts for that promoter. The promoters in the “++” class indicate higher performance.
[0150] Table 4 below shows the expression score for each indicated promoter in Hela and AML 12 cells.Table 4. Expression Score for Indicated Promoter in Hela and AML12 Cells.Promoter ID AML12 Cells Hela Cells1 ++ ++2 ++ ++3 + ++4 + +5 + +6 + +* * *
[0151] The invention is not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described will become apparent to those skilled in the art from the foregoing description and accompanying figures. Such modifications are intended to fall within the scope of the appended claims.
[0152] All references (e.g., publications or patents or patent applications) cited herein are incorporated herein by reference in their entireties and for all purposes to the same extent as if each individual reference (e.g., publication or patent or patent application) was specifically and individually indicated to be incorporated by reference in its entirety for all purposes. Other embodiments are within the following claims.
Claims
Attorney Docket No.: 62801.89W001CLAIMSWhat is Claimed Is:
1. An isolated DNA molecule comprising an engineered promoter comprising a nucleotide sequence at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the nucleotide sequence set forth in any one of SEQ ID NOS: 1-8.
2. An isolated DNA molecule comprising, in the following order,an engineered promoter comprising a nucleotide sequence at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the nucleotide sequence set forth in any one of SEQ ID NOS: 1-8; andan open reading frame encoding an RNA transcript or protein.
3. The isolated DNA molecule of claim 1 or 2, wherein the engineered promoter comprises a nucleotide sequence at least 90%. 91%, 92%, 93%, 94%, 95%. 96%, 97%, 98%, 99%, or 100% identical to the nucleotide sequence set forth in any one of SEQ ID NOS: 1-8.
4. The isolated DNA molecule of any one of claims 1-3, wherein the engineered promoter comprises a nucleotide sequence at least 95%, 96%, 97%, 98%, 99%, or 100% identical to the nucleotide sequence set forth in any one of SEQ ID NOS: 1-8.
5. The isolated DNA molecule of any one of claims 1-4, wherein the engineered promoter comprises the nucleotide sequence set forth in any one of SEQ ID NOS: 1-8.
6. The isolated DNA molecule of any one of the preceding claims, wherein the nucleotide sequence of the engineered promoter is less than 100% (e.g., less than 99%, 98%, 97%, 96%, 95%, 94%, 93%. 92%, 91%, or 90%) identical to the nucleotide sequence set forth in SEQ ID NO: 9.
7. The isolated DNA molecule of any one of the preceding claims, wherein the nucleotide sequence of the engineered promoter comprises at least one (e.g., 1. 2, 3, 4, 5, 6, 7, 8, 9.
10. 11.12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39) nucleotide variation (e.g., substitution) relative to the nucleotide sequence set forth in SEQ ID NO: 9.
8. An isolated DNA molecule comprising an engineered promoter comprising a nucleotide sequence at least 80%, 81%, 82%, 83%, 84%. 85%. 86%, 87%, 88%, 89%. 90%. 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, identical to the nucleotide sequence set forth in SEQ IDAttorney Docket No.: 62801.89W001NO: 9 and comprises one or more nucleotide variation (e.g., substitution) relative to the nucleotide sequence set forth in SEQ ID NO: 9.
9. The isolated DNA molecule of any one of the preceding claims, wherein the engineered promoter can increase expression of a transcript or protein encoded by the open reading frame, relative to a DNA molecule comprising a reference promoter.
10. The isolated DNA molecule of any one of the preceding claims, wherein the engineered promoter can increase expression of a transcript or protein encoded by the open reading frame, relative to a DNA molecule comprising a reference promoter comprising the nucleotide sequence set forth in SEQ ID NO: 9.
11. The isolated DNA molecule of any one of the preceding claims, wherein the DNA molecule comprises an inverted terminal repeat (ITR).
12. The isolated DNA molecule of any one of the preceding claims, wherein the DNA molecule comprises a 5' ITR and a 3' ITR.
13. The isolated DNA molecule of any one of the preceding claims, wherein the DNA molecule comprises, in the following order, a 5' ITR, the engineered promoter, the open reading frame, and a 3' ITR.
14. The isolated DNA molecule of any one of the preceding claims, wherein the DNA molecule comprises one or more regulatory elements (e.g., transcriptional regulatory elements).
15. The isolated DNA molecule of any one of the preceding claims, wherein the DNA molecule comprises one or more transcriptional regulatory elements.
16. The isolated DNA molecule of any one of the preceding claims, wherein the DNA molecule comprises an enhancer.
17. The isolated DNA molecule of any one of the preceding claims, wherein the DNA molecule comprises an intron.
18. The isolated DNA molecule of any one of the preceding claims, wherein the DNA molecule comprises transcription termination sequence.
19. The isolated DNA molecule of any one of the preceding claims, wherein the DNA molecule comprises a posttranscriptional regulatory element.
20. The isolated DNA molecule of any one of the preceding claims, wherein the DNA molecule comprises a poly(A) signal sequence.Attorney Docket No.: 62801.89W00121. The isolated DNA molecule of any one of the preceding claims, wherein the DNA molecule comprises one or more untranslated region (UTR).
22. The isolated DNA molecule of any one of the preceding claims, wherein the DNA molecule comprises a 5' untranslated region.
23. The isolated DNA molecule of any one of the preceding claims, wherein the DNA molecule comprises a 3' UTR.
24. The isolated DNA molecule of any one of the preceding claims, wherein the DNA molecule comprises a 5' UTR and a 3' UTR.
25. The isolated DNA molecule of any one of the preceding claims, wherein the open reading frame encodes a protein.
26. The isolated DNA molecule of any one of the preceding claims, wherein the protein is a therapeutic protein.
27. The isolated DNA molecule of any one of the preceding claims, wherein the protein (e.g., therapeutic protein) is an immunogen (e.g., viral, bacterial, fungal).
28. The isolated DNA molecule of any one of the preceding claims, wherein the protein e.g., therapeutic protein) comprises an antibody (or a functional fragment or variant thereof) or a fusion protein.
29. The isolated DNA molecule of any one of the preceding claims, wherein the protein (e.g., therapeutic protein) is a hormone, enzyme, growth factor, blood protein, a clotting factor, transcription factor, cytokine, chemokine, chimeric antigen receptor, T-cell receptor, or nuclease (e.g., endonuclease).
30. The isolated DNA molecule of any one of the preceding claims, wherein the open reading frame encodes an RNA transcript.
31. The isolated DNA molecule of any one of the preceding claims, wherein the RNA transcript is a tRNA, miRNA, siRNA, antisense oligonucleotides (ASO), IncRNA, rRNA, microRNA, piRNA, snoRNA, snRNA, exRNA, scaRNA, Y RNA, or hnRNA.
32. The isolated DNA molecule of any one of the preceding claims, comprising a plurality of open reading frames, each encoding an RNA transcript or protein.
33. The isolated DNA molecule of any one of the preceding claims, wherein each open reading frame of the plurality encodes a protein.Attorney Docket No.: 62801.89W00134. The isolated DNA molecule of any one of the preceding claims, wherein each open reading frame of the plurality encodes a different protein.
35. The isolated DNA molecule of any one of the preceding claims, wherein each open reading frame of the plurality encodes an RNA transcript.
36. The isolated DNA molecule of any one of the preceding claims, wherein each open reading frame of the plurality encodes a different RNA transcript.
37. A vector comprising the DNA molecule of any one of claims 1-36.
38. The vector of claim 37, wherein the vector is a plasmid or a viral vector.
39. A carrier comprising the DNA molecule of any one of claims 1-36 or the vector of any one of claims 37-38.
40. The carrier of claim 39, wherein the carrier is a lipid nanoparticle (LNP), liposome, lipoplex, or nanoliposome.
41. The carrier of claim 40, wherein the carrier is an LNR42. The carrier of claim 40 or 41, wherein the LNP comprises a cationic lipid, a neutral lipid, a cholesterol, and / or a PEG lipid.
43. The carrier of any one of claims 40-42, wherein the LNP comprises a cationic lipid, a neutral lipid, a cholesterol, and a PEG lipid.
44. The carrier of any one of claims 40-43, wherein the LNP has a mean particle size of between 80 nm and 160 nm.
45. A cell (e.g., host cell) or a population of cells (e.g., a population of host cells) comprising the DNA molecule of any one of claims 1-36, the vector of any one of claims 37-38, or the earner of any one of claims 39-44.
46. A pharmaceutical composition comprising the DNA molecule of any one of claims 1-36, the vector of any one of claims 37-38, the carrier of any one of claims 39-44, or the cell or population of cells of claim 45. and a pharmaceutically acceptable excipient.
47. A vaccine composition comprising the DNA molecule of any one of claims 1-36, the vector of any one of claims 37-38, the carrier of any one of claims 39-44, the cell or population of cells of claim 45, or the pharmaceutical composition of claim 46.
48. The vaccine composition of claim 47, wherein the protein (e.g., therapeutic protein) comprises an immunogen.Attorney Docket No.: 62801.89W00149. A kit comprising the DNA molecule of any one of claims 1 -36, the vector of any one of claims 37-38, the carrier of any one of claims 39-44, or the cell or population of cells of claim 45, the vaccine composition of any one of claims 47-48, or the pharmaceutical composition of claim 46, and optionally comprising instructions for use of the foregoing.
50. An in vitro method of making a protein (e.g., a therapeutic protein), the method comprising(a) culturing a population of cells in vitro,(b) introducing the DNA molecule of any one of claims 1-36, the vector of any one of claims 37-38, or the carrier of any one of claims 39-44, to the population of cells; and(c) culturing the population of cells under conditions and for a period of time sufficient to allow for expression of the protein (e.g., therapeutic protein); and(d) optionally isolating and / or purifying the expressed protein (e.g., therapeutic protein).
51. A method of delivering a DNA molecule, a vector, or a carrier to a cell, the method comprising delivering to the cell the DNA molecule of any one of claims 1-36. the vector of any one of claims 37-38, the carrier of any one of claims 39-44, or the cell or population of cells of claim 45, the vaccine composition of any one of claims 47-48, or the pharmaceutical composition of claim 46, to thereby deliver the DNA molecule, the vector, or the carrier to the cell.
52. The method of claim 51, wherein the method is in vitro.
53. The method of claim 51, wherein the cell is in vitro or ex vivo.
54. The method of claim 51, wherein the cell is in a subject.
55. A method of delivering a DNA molecule, a vector, a carrier, a cell, vaccine composition, or pharmaceutical composition to a subject in need thereof, the method comprising administering to the subject the DNA molecule of any one of claims 1-36, the vector of any one of claims 37-38, the carrier of any one of claims 39-44, or the cell or population of cells of claim 45, the vaccine composition of any one of claims 47-48, or the pharmaceutical composition of claim 46, to thereby deliver the DNA molecule, the vector, the carrier, the cell, the vaccine composition, or the pharmaceutical composition to the subject.
56. A method of expressing a protein (e.g., a therapeutic protein) in a cell, the method comprising delivering to the cell the DNA molecule of any one of claims 1-36, the vector of any one of claims 37-38, the carrier of any one of claims 39-44, or the cell or population of cells ofAttorney Docket No.: 62801.89W001claim 45, the vaccine composition of any one of claims 47-48, or the pharmaceutical composition of claim 46, to thereby express the protein in the cell.
57. The method of claim 56, wherein the method is in vitro.
58. The method of claim 56, wherein the cell is in vitro or ex vivo.
59. The method of claim 56, wherein the cell is in a subject.
60. A method of expressing a protein (e.g., a therapeutic protein) in a subject in need thereof, the method comprising administering to the subject the DNA molecule of any one of claims 1-36, the vector of any one of claims 37-38, the carrier of any one of claims 39-44, or the cell or population of cells of claim 45, the vaccine composition of any one of claims 47-48, or the pharmaceutical composition of claim 46, to thereby express the protein (e.g., therapeutic protein) in the subject.
61. A method of treating, ameliorating, or preventing a disease in a subject in need thereof, the method comprising administering to the subject the DNA molecule of any one of claims 1-36, the vector of any one of claims 37-38, the carrier of any one of claims 39-44, or the cell or population of cells of claim 45, the vaccine composition of any one of claims 47-48, or the pharmaceutical composition of claim 46, to thereby treat, ameliorate, or prevent the disease in the subject.
62. A method of treating, ameliorating, or preventing a disease in a subject in need thereof, the method comprising administering to the subject the protein made by the method of any one of claims 56-59 (or a pharmaceutical composition comprising the same), to thereby treat, ameliorate, or prevent the disease in the subject.
63. The method of claim 61 or 62, wherein the disease is a proinflammatory disease (e.g., an autoimmune disease), an immunosuppressive disease, a cancer, a hormone related disease, a growth factor related disease, a blood clotting disease, or a genetic disease.
